European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions

Christian Pristipino*, MD; Peter Germonpré², MD; Danilo Toni³, MD; Horst Sievert⁴,⁵,⁶, MD; Bernhard Meier⁷, MD; Fabrizio D’Ascenzo⁸, MD; Sergio Bertii⁹, MD; Eustaquio Maria Onorato¹⁰, MD; Francesco Bedogni¹¹, MD; Jean-Louis Mas¹², MD; Paolo Scacciatella¹³, MD; David Hildick-Smith¹⁴, MD; Fiorenzo Gaita¹⁵, MD; Paul A. Kyrle¹⁶, MD; John Thomson¹⁷, MD; Genevieve Derumeaux¹⁸, MD; Dirk Sibbing¹⁹, MD; Massimo Chessa¹⁰, MD; Marius Hornung⁴, MD; Jose Zamorano¹⁰, MD; Dariusz Dudek¹⁰,²¹, MD

EVIDENCE SYNTHESIS TEAM: Fabrizio D’Ascenzo (lead)⁸, MD; Pierluigi Omedè⁶, MD; Flavia Ballocca²², MD; Umberto Barbero²³, MD; Francesca Giordana²⁴, MD; Sebastiano Gili², MD; Mario Ianmaccorre², MD

INTERNATIONAL EXPERTS: Teiji Akagi²⁶, MD, Gianpaolo Anzola²⁷, MD; John Carroll²⁸, MD; Bharat Dalvi²⁹, MD; Claudio De Angelis³⁰, MD; Ge Junbo³¹, MD; Scott E. Kasner³², MD; Ina Michel-Behnke³³, MD; Giuseppe Musumeci³⁴, MD; Lars Søndergaard³⁵, MD; Giuseppe Tarantini³⁶, MD; Giuseppe G.L. Biondi-Zoccai³⁷,³⁸, MD; joint task force of European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Stroke Organisation (ESO), European Heart Rhythm Association (EHRA), European Association for Cardiovascular Imaging (EACVI), European Paediatric and Congenital Cardiology (AEPC), ESC Working Group on Adult Congenital Heart Disease, ESC Working Group on Thrombosis, European Haematological Society (EHA), European Underwater and Baromedical Society (EUBS)

EAPCI SCIENTIFIC DOCUMENTS AND INITIATIVES COMMITTEE: Davide Capodanno³⁹, MD, PhD; Marco Valgimigli³, MD, PhD; Robert Byrne⁴⁰, MB, BCh, PhD; Vijay Kunadian⁴¹, MD

1. S. Filippo Neri Hospital ASL Roma 1, Rome, Italy; 2. Military Hospital, Brussels, Belgium; 3. Hospital Policlinico Umberto I, Sapienza University, Rome, Italy; 4. CardioVascular Center Frankfurt (CVC Frankfurt), Frankfurt, Germany; 5. Anglia Ruskin University, Chelmsford, United Kingdom; 6. University California San Francisco (UCSF), San Francisco, CA, USA; 7. University Hospital, Bern, Switzerland; 8. Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy; 9. Heart Hospital, Massa, Italy; 10. Centro Cardiologico Monza, IRCCS, Milan, Italy; 11. IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy; 12. Hôpital Sainte-Anne, Université Paris Descartes, Paris, France; 13. U. Parini Hospital, Aosta, Italy; 14. Sussex Cardiac Centre, Brighton and Sussex University Hospitals, Brighton, United Kingdom; 15. Medical University, Vienna, Austria; 16. Leeds General Infirmary, Leeds, United Kingdom; 17. Hôpital Henri Mondor, Faculté de Médecine de Créteil, Créteil, France; 18. Privatklinik Laurthallicher Mühle am Ostersee, Iffeldorf and Ludwig-Maximilians-Universität (LMU) München, Munich, Germany; 19. University Hospital Ramón y Cajal, Madrid, Spain; 20. Jagiellonian University Medical College, Krakow, Poland; 21. Maria Cecilia Hospital, GVM Care & Research, Coigüela (RA), Italy; 22. Ospedale Maria Vittoria, Turin, Italy; 23. Ospedale Civile SS. Annunziata, Savigliano, Italy; 24. Ospedale San Giovanni Bosco, Turin, Italy; 25. Ospedale Santa Croce e Carle, Cuneo, Italy; 26. Okayama University Medical School, Okayama, Japan; 27. Brescia University, Brescia, Italy; 28. University of Colorado Hospital, Denver, CO, USA; 29. Glenmark Cardiac Centre, Mumbai, India; 30. Italian Air Force HQ, Rome, Italy; 31. Shanghai Institute of Cardiovascular Disease, Shanghai, China; 32. University of Pennsylvania, Philadelphia, PA, USA; 33. University Hospital for Children and Adolescents, Medical University Vienna, Vienna, Austria; 34. Mauriziano Hospital, Turin, Italy; 35. Rigshospitalet, Copenhagen, Denmark; 36. Padua University Hospital, Padua, Italy; 37. Sapienza University of Rome, Latina, Italy; 38. Mediterranea Cardiocentro, Naples, Italy; 39. Azienda Ospedaliero-Universitaria “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy; 40. RCSU University of Medicine and Health Sciences, Dublin, Ireland; 41. Newcastle University and Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

GUEST EDITOR: Franz-Josef Neumann, MD; Department of Cardiology and Angiology II, University Heart Center Freiburg - Bad Krozingen, Bad Krozingen, Germany

This paper also includes supplementary data published online at: https://eurointervention.pcronline.com doi/10.4244/EIJ-D-20-00785

*Corresponding author: San Filippo Neri - ASL Roma 1 Hospital, Viale Vaticano 68A, 00165 Roma, Italy.
E-mail: pristipino.c@gmail.com

All rights reserved. © 2021 the Author(s).
Abstract
Patent foramen ovale (PFO) is implicated in the pathogenesis of a number of medical conditions but to date only one official position paper related to left circulation thromboembolism has been published. This interdisciplinary paper, prepared with the involvement of eight European scientific societies, reviews the available evidence and proposes a rationale for decision making for other PFO-related clinical conditions. In order to guarantee a strict evidence-based process, we used a modified grading of recommendations, assessment, development, and evaluation (GRADE) methodology. A critical qualitative and quantitative evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk/benefit ratio. The level of evidence and the strength of the position statements were weighed and graded according to predefined scales. Despite being based on limited and observational or low-certainty randomised data, a number of position statements were made to frame PFO management in different clinical settings, along with suggestions for new research avenues. This interdisciplinary position paper, recognising the low or very low certainty of existing evidence, provides the first approach to several PFO-related clinical scenarios beyond left circulation thromboembolism and strongly stresses the need for fresh high-quality evidence on these topics.

Abbreviations
- B&T: behavioural and technical
- CO₂: carbon dioxide
- COPD: chronic obstructive pulmonary disease
- CSD: cortical spreading depression
- CT: computerised tomography
- c-TCD: contrast-enhanced transcranial Doppler
- c-TTE: contrast-enhanced transthoracic echocardiography
- DCS: decompression sickness
- EAPCI: European Association of Percutaneous Cardiovascular Interventions
- FiO₂: fraction of inspired oxygen
- GRADE: grading of recommendations assessment, development, and evaluation
- HAPO: high-altitude pulmonary oedema
- MRI: magnetic resonance imaging
- NYHA: New York Heart Association
- OSAS: obstructive sleep apnoea syndrome
- PaO₂: partial pressure of oxygen in the blood
- PICO: population-intervention-comparator-outcome
- PFO: patent foramen ovale
- POS: platypnoea-orthodeoxia syndrome
- PRISMA:Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- RCT(s): randomised clinical trial(s)
- R-T-L: right-to-left
- SaO₂: oxygen haemoglobin saturation
- SMD: standardised mean difference
- SpO₂: peripheral capillary oxygen saturation
- TCD: transcranial Doppler
- TOE: transoesophageal echocardiography
- VGE: venous gaseous emboli

Introduction
Patent foramen ovale (PFO) is implicated in the pathogenesis of a number of medical conditions. However, the high prevalence of a PFO in the normal population (20-30%) implies that PFO can often be an incidental finding rather than a causative one. To help clinicians with decision making, the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Scientific Documents and Initiatives Committee invited eight European scientific societies and international experts to develop interdisciplinary position statements on the management of PFO, based on systematic assessments of the literature.

A previous position paper has been published addressing issues related to cryptogenic thromboembolism. The present paper reports the approach to patients with PFO and decompression sickness, desaturation syndromes, migraine, and other clinical presentations.

Methods
To guarantee a strictly evidence-based process, position statements were developed using modified grading of recommendations assessment, development, and evaluation (GRADE) methodology (http://gdt.guidelinedevelopment.org/app/handbook/handbook.html), and by answering population-intervention-comparator-outcome (PICO) questions and non-PICO questions. A detailed review of the methodology employed can be found in Supplementary Appendix 1 and in an appendix of the previously published first part of this position paper. Systematic reviews and statistical analysis were performed by a dedicated evidence synthesis team. A detailed insight and discussion of each section and the most important paragraphs can be found in Supplementary Appendix 2.

DECOMPRESSION SICKNESS
Decompression sickness (DCS) is a complex condition triggered by the trapping of gas emboli in vessels and tissues, which can result in a wide range of acute clinical scenarios, from mild to severe, with possible persistent disability or death. DCS occurs when a person moves from a higher pressure to a lower pressure area, such as a rapid ascent at high altitude or a rapid ascent from depth (compressed air work or diving). A PFO can allow paradoxical embolisation of venous gaseous emboli (VGE) when there is a rise in right heart pressures due to pulmonary gas embolism or physical exercise; however, in large PFOs with spontaneous right-to-left (R-T-L) shunts, paradoxical VGE can also occur without other provocation.

Mild embolism may cause subclinical lesions, with still unknown late consequences, while decompression sickness can severely affect the patient and even lead to fatality.

The risk of DCS from diving is difficult to estimate, but an incidence up to approximately 1.5% has been reported. In divers, the association between PFO and DCS is supported by retrospective...
case-controlled epidemiological studies, mechanistic studies and association studies. In our meta-analysis of four correlation studies comparing the prevalence of R-T-L shunts in patients with and without DCS, we found an odds ratio (OR) of 5.63 (95% CI: 3.14-10.09) for R-T-L shunts in patients with DCS\textsuperscript{11-14} (Supplementary Figure 1).

The occurrence of altitude DCS is lower and is decreasing over time. High-altitude military pilots with long flights in a hypobaric environment (i.e., U2 plane pilots) may have short-term and long-term complications\textsuperscript{15-17} but there are no studies published about correlation with cardiac defects. Therefore, the role of PFO in individual cases of altitude DCS can remain elusive\textsuperscript{6,7,18,19}.

IS IT CLINICALLY POSSIBLE TO ESTIMATE THE PROBABILITY OF A CAUSAL RELATIONSHIP BETWEEN A PFO AND DECOMPRESSION SICKNESS?

Determination of a causal role of PFO in DCS is difficult and should take into account that systematic and prospective evaluations of PFO-associated DCS are lacking; considerations can only be based on case reports, retrospective and mechanistic studies. Therefore, an individual assessment is mandatory. PFO-related DCS can produce earlier and more abundant VGE arterialisation but its role should be weighed against other individual factors that affect VGE production and trapping (dive/flight characteristics, physiological characteristics of tissues and factors that influence the threshold of “VGE tolerance”). Therefore, a technical analysis of the pre-decompression and decompression phase characteristics of each particular case is necessary\textsuperscript{19}. In professional divers suffering from PFO-associated DCS, PFO size has been found to be a predictor of recurrence\textsuperscript{21,22}. The main characteristics which can be considered are summarised in Supplementary Table 1, with position statements in Supplementary Table 2.

DIAGNOSTIC WORKUP

Patients with a history of DCS should have a thorough workup to identify factors that may have led to the occurrence of DCS. DCS has multiple and non-specific clinical manifestations (Supplementary Table 3)\textsuperscript{23}; there are no imaging or laboratory test patterns which are unequivocal for DCS. Therefore, the diagnosis of DCS should be made by an experienced hyperbaric or aerospace physician according to the characteristics of the exposure, symptoms and the absence of other causes. VGE detected by echocardiography in patients with suspected DCS reinforces the diagnosis\textsuperscript{24}.

High-resolution computerised tomography (CT) scanning and pulmonary function testing with bronchial provocation testing can exclude alveolar barotrauma but should not delay prompt recompression treatment of DCS.

When the diagnosis of DCS is unlikely, it may be unnecessary to begin secondary prevention workup even if a PFO is known to be present. In cases of DCS where no obvious risk factors for DCS can be identified or in activities with a high but non-modifiable risk of DCS, PFO screening should be considered part of the diagnostic workup.

PFO screening should be carried out at experienced sites, employing the previously published diagnostic approach\textsuperscript{1,2} to minimise false-negative tests, which could increase DCS risk during subsequent activities due to a false sense of security\textsuperscript{25,26}.

When a clear, modifiable cause can be identified (e.g., diving outside acceptable decompression limits), or when more than two risk factors known to increase the risk for DCS are present (e.g., dehydration; heavy exercise at depth or at height; diving while cold near the end of the dive causing peripheral vasoconstriction; alcohol consumption), screening for PFO is not generally recommended\textsuperscript{27}.

Figure 1 displays the recommended stepwise approach to DCS.

SECONDARY PREVENTION

There are no published randomised studies comparing PFO closure to behavioural prevention of DCS. Moreover, limited observational evidence in divers is available and no data are available for aircrews. However, on any occasion, inhibiting the production of VGE has the potential to prevent further DCS, irrespective of the presence of a PFO\textsuperscript{28,29}. This can be achieved by: a) modifying the individual’s lifestyle and personal physiologic characteristics (smoking and alcohol consumption, body weight, ensuring adequate hydration pre and post dive); b) avoiding those technical dive or flight factors that have caused abnormal VGE production; and c) reducing the inert gas saturation of tissues before decompression by breathing high concentrations of oxygen before the ascent (Supplementary Table 4).

Nonetheless, there are certain categories of aircrew or diver for whom performing conservative flights or dives is not a realistic option\textsuperscript{27,30}. In these people, PFO closure may be proposed based on observational data suggesting that PFO closure is associated with reduced DCS incidence in divers\textsuperscript{5} and prevents arterialisation of VGE\textsuperscript{31-33}. However, since recurrent DCS has also been observed

\begin{figure}
\centering
\includegraphics[width=\textwidth]{flowchart.png}
\caption{Flow chart depicting strategy for investigation after DCS. R.F.: risk factors}
\end{figure}
after PFO closure in some studies, it should be remembered that diving may be a cause of DCS even without a PFO\textsuperscript{33-35}. Current recommendations are that diving should be resumed only in the presence of a sealed PFO\textsuperscript{30,36}. In the absence of complete closure post procedure, divers should not be allowed to return to "unrestricted" diving and should only make low-risk dives.

Figure 2 displays the treatment algorithm developed by this task force; Supplementary Table 2 displays the position statements.

Figure 2. Flow chart for therapeutic decision making for DCS. R.F.: risk factors

IS A PRIMARY SCREENING OR PREVENTION ADVISED?
No evidence-based statements can be formulated regarding PFO closure as primary prevention of DCS.

General lifestyle and behavioural changes and technical procedure adherence are usually indicated in both divers and flying crews.

Based on the mismatch between the high prevalence of PFO and low incidence of DCS, it is suggested that primary screening for PFO should not be carried out on a routine basis in either divers or conventional altitude pilots\textsuperscript{30,36-38}.

However, in professional divers, primary screening for PFO can be foreseen in accurately selected cases with high-risk work activity, in order to evaluate the possibility of a primary percutaneous closure. On the same basis, primary screening for PFO could be carried out in select military pilots performing intensive very high-altitude flight activities\textsuperscript{36,37}. However, primary PFO closure in pilots should be weighed against the possibility of disqualification from flight activity.

When a PFO is an incidental finding in pilots or divers with no history of DCS, no restriction in conventional altitude flights is required, while recreational divers should be counselled by an experienced diving physician either to stop diving, or to undertake only low-risk profile dives. PFO closure indications should always be considered in conjunction with an experienced diving or aerospace physician.

PRACTICAL SUMMARY 1: DECOMPRESSION SICKNESS

WHAT TO DO
– PFO screening in DCS cases with no obvious risk factors or with high but non-modifiable risk for DCS
– After a DCS, primarily prevent bubbles with behavioural and technical (B&T) changes
– If B&T changes are not possible or not effective, PFO closure can be proposed with shared decision making underscoring the lack of evidence
– Resume unrestricted activity only after confirmed PFO sealing post intervention

WHAT NOT TO DO
– Primary PFO screening
– Deny conventional flight or diving after incidental finding of PFO
– High-risk recreational dives after incidental finding of PFO
– Propose PFO closure if B&T changes can be made and are effective

MIGRAINE
Migraine is a common disorder which affects approximately 12% of the general population (4-9% of men and 15%-17% of women between 20 and 64 years of age\textsuperscript{39}) and is often disabling\textsuperscript{40}. It is estimated that 1-4% of the population meet the criteria for chronic migraine\textsuperscript{41,42}. In the general population, it is estimated that the prevalence of migraine with aura ranges from 1 to 4% in men and 3 to 10% in women\textsuperscript{41}.

Position statements are summarised in Supplementary Table 5.

IS PFO ASSOCIATED WITH MIGRAINE? WHAT ARE THE UNDERLYING MECHANISMS?
The association between PFO and migraine has been suggested by a higher prevalence of PFO in those with migraine, especially among those with aura, than in the general population\textsuperscript{44-51} and by the finding of incidental improvement in migraine in patients who have undergone percutaneous closure of the PFO for other reasons\textsuperscript{52,53}. Moreover, the high prevalence of migraine attacks in some disorders wherein atrial or pulmonary shunts exist\textsuperscript{54,55} would suggest a pathogenic role of R-T-L shunts.

However, the association between migraine and PFOs varies considerably across heterogeneous populations\textsuperscript{46,56-60}.

The most plausible electrophysiological substrate of headaches and aura symptoms is cortical spreading depression (CSD)\textsuperscript{61,62} which, in this case, would be triggered by paradoxical cerebral thromboembolism\textsuperscript{45,47,49,61,63-67} and/or the direct passage of metabolites into the systemic circulation, also possibly caused by the release of active metabolites from platelets activated by shear stress in the PFO, resulting in irritation of the trigeminal nerve and the brain’s vascular network\textsuperscript{57,68}.
IS IT CLINICALLY POSSIBLE TO ESTIMATE THE PROBABILITY OF A CAUSAL RELATIONSHIP BETWEEN A PFO AND MIGRAINE?

In some retrospective and prospective observational studies, a higher prevalence of an atrial septal aneurysm (ASA) and larger PFO sizes in subjects with migraine with aura has been reported. Also, the number of bubbles crossing the PFO, as detected by contrast transcranial Doppler (cTCD), has been found to correlate with the severity and frequency of attacks among migraineurs with aura in other studies. However, the results of other studies do not support an association between the frequency of migraine attacks and PFO characteristics.

In patients with previous stroke, an association between PFO and migraine has been reported, and percutaneous closure has been shown to be more effective at reducing the frequency and severity of migraine attacks than in patients without cerebrovascular disease.

Older age seems to be associated with an absence of any relationship between PFO and migraine.

TREATMENT

To date, three randomised studies and three meta-analyses have addressed the issue of percutaneous closure as therapy for migraine. We performed an updated meta-analysis of randomised and observational studies to support the position statements in this document.

Observational studies yielded a statistically significant improvement in migraine, albeit with marked inconsistency between studies, whereas individual randomised clinical trials (RCTs) and their meta-analyses failed to demonstrate any statistically significant difference in primary outcomes, responder rates or complete migraine resolution. On the other hand, a meta-analysis of secondary endpoints revealed a statistically significant reduction in migraine attack frequency and duration. Also, subgroups of patients with aura and patients with cerebrovascular disease experienced statistically significant improvement in migraine with PFO closure, when compared to medical therapy (Supplementary Figure 2-Supplementary Figure 4).

One thing to be considered is that, according to GRADE methodology, the certainty of effects was judged severely, implying that a number of limitations need to be addressed in future studies (Supplementary Table 6). Moreover, it is possible that the neutral primary results of PFO closure studies may be due to the inclusion of patients without a causative PFO. Additionally, the choice of migraine study endpoints is problematic, being largely arbitrary. Therefore, further RCTs are necessary to obtain satisfactory certainty of effects.

Supplementary Table 7 shows the GRADE table for the treatment of migraine and Figure 3 summarises the proposed treatment algorithm, according to the statements.

Detailed answers to the PICO question and the detailed characteristics of the considered studies are displayed in Supplementary Table 8 and Supplementary Table 9.

PRACTICAL SUMMARY 2: MIGRAINE

WHAT TO DO

– Treat migraine with conventional therapies
– Consider PFO closure only in clinical trials or for compassionate use in migraine with aura

WHAT NOT TO DO

– Consider PFO closure as part of a routine treatment algorithm

ARTERIAL DEOXYGENATION SYNDROMES

Arterial hypoxaemia is a decrease in the content of oxygen in the blood (SaO2 or SpO2 <90% or PaO2 <60 mmHg), with or without cyanosis. Its main symptoms are exertional and/or resting dyspnoea.

Figure 3. Algorithm for the management of PFO-associated migraine. Rx: therapy
PFO has been associated with several arterial deoxygenation syndromes. Up to 30% of patients with a PFO were discovered to have clinically significant arterial deoxygenation during effort in one study. To date, only a few studies have been published on this topic. These are summarised in Supplementary Table 10.

**CAN PFO BE ASSOCIATED WITH ARTERIAL HYPOXAEIA?**

**WHAT ARE THE UNDERLYING MECHANISMS?**

Several case reports and some experimental and clinical studies have demonstrated that a shunt through a PFO has the potential to cause arterial deoxygenation by mixing venous and arterial blood. In most cases, the PFO shunt only aggravates pre-existing causes of hypoxaemia.

All the causes that elevate pressure in the right heart chambers, such as pulmonary hypertension, can also increase minor shunts. However, several anatomical conditions may also cause a significant shunt, even in the presence of normal mean right atrial pressure (Supplementary Table 10).

**DIAGNOSTIC WORKUP**

Prior to considering a PFO, an in-depth interdisciplinary diagnostic workup, specific for each clinical syndrome, should be performed to assess the contribution of different potential causes of hypoxaemia, and the pre-test probability of a PFO role in each syndrome should be considered (Supplementary Table 10). The evaluation should be performed and discussed at least by a cardiologist and a pulmonologist.

Every situation in which the baseline condition does not fully explain symptoms and/or the hypoxaemia indicates a need to consider assessing a possible contribution of the PFO.

The diagnostic workup for PFO was published in the first part of this paper.

In the infrequent case of platypnoea-orthodeoxia syndrome (POS), the most common cause is a PFO; however, other cardiac and non-cardiac conditions should be ruled out with appropriate tests. A bubble test should be obtained during cardiac imaging with the patient in both a supine and an upright position. The presence of a persistent prominent Eustachian valve may lead to diversion of blood flow from the inferior vena cava towards a PFO. This effect could be exacerbated by atrial deformities and may also lead to a false-negative result during contrast-enhanced transthoracic echocardiography (c-TTE) or contrast transoesophageal echocardiography (c-TOE) via the antecubital vein. A femoral vein contrast injection may be considered in case of high suspicion for POS, prominent Eustachian valve and negative contrast exams.

In obstructive sleep apnoea syndrome (OSAS), it is important to assess the number and severity of episodes of desaturation on therapy to evaluate the possible role of PFO in clinical findings.

Exercise hypoxaemia is significant when there is an SaO₂ or SpO₂ drop ≥8% from baseline, or to a level <90%.

In all syndromes, a lower-than-expected or absent increase in SaO₂ or SpO₂ with FiO₂ 1.0 suggests a significant intracardiac shunt.

Whenever possible, an invasive evaluation of pulmonary pressure to rule out severe pulmonary hypertension and SaO₂ measurements (in the left atrium and each pulmonary vein) should be performed to document a step-down in SaO₂ while excluding pulmonary abnormalities (pulmonary embolism or intrapulmonary shunts). Moreover, during catheterisation, an occlusion test can demonstrate increased systemic saturation.

**IS IT CLINICALLY POSSIBLE TO ESTIMATE THE PROBABILITY OF A CAUSAL RELATIONSHIP BETWEEN A PFO AND HYPOXAEIA?**

Evaluating the role of a PFO in hypoxaemia is difficult and should encompass all the patient’s clinical, imaging and functional data.

In the few available observational studies that have been published, larger and more durably open PFO were the characteristics which correlated more frequently with hypoxaemia in different clinical syndromes.

Invasive measurement of intracardiac arterial oxygen saturation is a key tool for decision making. However, one must consider interference of the catheter in PFO shunting, as well as the difficulty of extrapolating the clinical impact of lab measurements in syndromes in which the opening of a PFO is intermittent.

**TREATMENT**

Treatment is based on severity of symptoms and the pathogenic role of PFO on shunting. Patients with chronic severe pulmonary hypertension should be excluded from interventional treatment.

No randomised trials have been performed addressing percutaneous closure of PFO in desaturation syndromes.

We performed a meta-analysis of observational before and after closure studies which reported SaO₂ or SpO₂ for two disparate hypoxaemia syndromes – POS and exertional desaturation. We found a statistically significant increase in SaO₂ or SpO₂ in both clinical conditions after PFO closure: in exercise desaturation 9.8% (95% CI: 7.1-12.5%) with a severe heterogeneity among studies (I²: 79%) and in POS 9.6% (95% CI: 5.7-13.5%) also with a severe heterogeneity among studies (I²: 82%) (Supplementary Figure 5).

In POS due to PFO and OSAS, the evidence for percutaneous closure is based on case reports, case series and small registries. The studies on POS revealed stable relief of symptoms up to five years with improved standing arterial oxygen saturation in all patients who did not have other dominating causes of hypoxaemia. In OSAS, one case-control observational study on 40 patients showed a statistically significant improvement in left ventricular diastolic function, in indices of apnoea and desaturation episodes and a reduction in systemic arterial pressure.

Only preliminary reports with good results are available for exertional desaturation and high-altitude pulmonary oedema (HAPO), whereas no data are available regarding PFO closure in chronic obstructive pulmonary disease (COPD) patients.

Taken together, these data show that percutaneous closure of PFO has the potential to impact on arterial oxygen saturation and improve symptoms in select patients with an arterial hypoxaemia syndrome. Randomised studies are required to demonstrate effectiveness and safety in these contexts. Position statements are listed in Supplementary Table 11.
SELECT HIGH-RISK CLINICAL CONDITIONS
PREGNANCY, DELIVERY AND THE PUERPERIUM
Pregnant women are at an increased risk of ischaemic and haemorrhagic stroke and venous thromboembolism compared to non-pregnant women, and PFO-related strokes do happen during pregnancy and the puerperium. However, to date, no large studies have addressed the question of whether PFO is a risk factor for stroke and systemic thrombotic embolisation under such conditions. Specific characteristics of PFO-associated stroke seem to emerge from an analysis of the available reports, but the evidence consists mainly of small case series, so no conclusions can be drawn. Moreover, no studies have been published testing different preventive approaches for PFO-related stroke. Relevant position statements are listed in Supplementary Table 12.

PREOPERATIVE EVALUATION IN NON-CARDIAC SURGERY
Perioperative stroke, with an incidence ranging from 0.2% to 7.9%, is a serious complication of surgical procedures, with significant consequences in terms of morbidity, duration of hospitalisation and mortality. The incidence of PFO-related stroke during and after surgery and anaesthesia may potentially be increased by haemodynamic changes, hypercoagulability, and the formation of venous thrombosis.

A recent large retrospective study involving 150,198 adult patients who underwent non-cardiac surgery and were extubated after the operation showed a statistically significant increased risk of perioperative ischaemic stroke in patients with a PFO (3.5% vs 0.5%). The incidence of stroke in patients with PFO was more significantly increased in otherwise low-risk stroke patients. Moreover, PFO was associated with larger strokes and with more severe neurological deficits and was linked to an increased risk of other systemic embolic complications.

However, there are neither prospective studies addressing these issues, nor RCTs assessing the effectiveness of pharmacotherapy or interventional procedures at decreasing risk.

Relevant position statements are listed in Supplementary Table 12.

NEUROSURGERY IN THE SITTING POSITION
During neurosurgery, after venous incision, a venous air embolism with severe immediate or delayed cardiopulmonary and cerebral complications can potentially occur. This occurs more frequently when patients are in a sitting position (up to 50-79% of cases). Adoption of this position has declined considerably, also because of other complications. Notwithstanding this, many surgical teams still place patients in a sitting position as a first choice to approach posterior fossa or dorsally located parietal lesions, because of the position’s advantages for surgeons. In patients with PFO, this results in paradoxical air embolism in up to 14% of the cases. For this reason, a prone position is usually considered mandatory in safety data. However, paradoxical air embolism can also happen when the patient is prone.

Diagnostic workup
The diagnostic workup to detect a PFO is described in part I of this document.

Prevention and treatment
Position statements are summarised in Supplementary Table 13.

PERIOPERATIVE MONITORING
During the procedure, patients can be monitored using transoesophageal echocardiography (TOE) and/or transcranial Doppler (TCD). Additionally, end tidal CO₂ detects clinically significant venous air emboli. Capnography is a readily available diagnostic tool, with moderate sensitivity and specificity for diagnosing air emboli. An alternative method is to measure expired nitrogen.

PFO CLOSURE
Since perioperative monitoring can make a timely diagnosis but cannot stop ongoing embolism, preoperative PFO closure has been proposed and presented in extremely limited preliminary reports with good results for the ensuing neurosurgical operation in the sitting position.

However, to date, no clinical studies have been published, and questions about the timing of surgery post intervention remain unanswered, especially regarding effective sealing of the defect, the endothelialisation of the device, and the duration of antiplatelet therapy.

Limitations
This position paper must not be read as a guideline. Indeed, when approaching the statements of this document, one should consider that the included conditions are often uncommon, their pathophysiology still incompletely known, and high-quality data regarding their management are still lacking. The ensuing result is an amount of sparse data with low or very low certainty of evidence. This, of course, has made it impossible to express conclusive focused indications but – since the patients suffering from these syndromes need treatment – has stimulated scientific societies to come together to express shared position statements in order to help approach these conditions rationally according to the available literature.
Conclusion
PFO comes into play in several pathogenic conditions, interacting with other causative processes in disparate dynamic networks. As a result, the heterogeneity of patients is high and evidence, where available, is weak. Therefore, therapeutic solutions often remain empiric, and will probably remain so for a long time due to the low number of patients with similar characteristics, which precludes adequately powered studies. Therefore, beyond the guidelines paradigm which cannot be applied in this context at the moment, this interdisciplinary position paper, based on a comprehensive and strict evaluation of the available data, may be useful for physicians to follow as a broad clinical approach. Nonetheless, based on the published research, we strongly underscore the need for new observational and randomised studies in order to allow the expression of conclusive indications for these poorly focused, and yet clinically relevant, syndromes.

Guest editor
This paper was guest edited by Franz-Josef Neumann, MD; Department of Cardiology and Angiology II, University Heart Center Freiburg - Bad Krozingen, Bad Krozingen, Germany.

Conflict of interest statement
R. Byrne reports personal fees from B. Braun Melsungen AG and from Biotronik, and grants from CeloNova Biosciences, outside the submitted work. B. Dalvi reports other financial activities from Abbott, outside the submitted work. D. Dudek reports grants and personal fees from Abbott, outside the submitted work. D. Hildick-Smith reports personal fees from Abbott, Gore, Occlutech, and Holistick, outside the submitted work. S.E. Kasner reports grants from W.L. Gore; during the conduct of the study, personal fees from Bristol-Myers Squibb and from Boehringer Ingelheim, and grants and personal fees from Medtronic and Bayer, outside the submitted work. J.L. Mas reports personal fees from Abbott, during the conduct of the study. B. Meier reports personal fees from Abbott, outside the submitted work. E.M. Onorato reports personal fees from Occlutech, outside the submitted work. P. Sciacchi reports grants from Abbott Medical and Gore Medical, outside the submitted work. H. Sievert reports reimbursement for clinical trials from 4tech Cardio, Abbott, Ablative Solutions, Ancora Heart, Append Medical, Axon, Bavaria Medizin Technologie GmbH, Bioventrix, Boston Scientific, Carag, Cardiac Dimensions, Cardiac Success, Cardimed, CeloNova, Comed B.V., Contego, CVRx, Dinova, Edwards, Endologix, Endomotic, Hemoteq, Hangzhou Nuomao Medtech, Holistick Medical, K2, Lifetech, Maquet Getinge Group, Medtronic, Mokita, Occlutech, Recor, Renal Guard, Terumo, Trisol, Vascular Dynamics, Vectorious Medtech, Venus, Venock, and Vivasure Medical, outside the submitted work. G. Tarantini reports personal fees from Abbott and Vascular Innovations, during the conduct of the study. J. Thomson reports personal fees from Gore Medical, outside the submitted work. T. Toni reports personal fees from Abbott, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, and Pfizer, outside the submitted work. The chairman of the Task Force and all the other authors declare no conflicts of interest for this work. The Guest Editor has no conflicts of interest to declare.

References
The references can be found in the Supplementary data document.

Supplementary data
Supplementary Appendix 1. Methods.
Supplementary Appendix 2. Detailed evaluation of specific issues.
Supplementary Figure 1. Meta-analysis of studies comparing the prevalence of R-T-L shunting in patients with and without DCS.
Supplementary Figure 2. Meta-analysis of observational and randomised trials regarding the incidence of persistent migraine comparing closure versus non-closure of PFO in studies with two cohorts.
Supplementary Figure 3. Meta-analysis of observational and randomised trials regarding the incidence of persistent migraine comparing closure versus non-closure of PFO in studies with two cohorts, by aura status.
Supplementary Figure 4. Meta-analysis of observational trials assessing persistence of migraine before and after PFO closure, by aura status.
Supplementary Figure 5. Meta-analysis of studies on PFO closure in desaturation syndromes. Improvement in blood oxygen saturation after PFO closure.
Supplementary Figure 6. PRISMA diagram of decompression sickness studies in recreational divers.
Supplementary Figure 7. PRISMA diagram of decompression sickness studies in professional divers.
Supplementary Figure 8. PRISMA diagram of decompression sickness studies in desaturation syndromes.
Supplementary Figure 9. PRISMA diagram of migraine studies.
Supplementary Table 1. Characteristics for the evaluation of a probable causal link between a PFO and DCS.
Supplementary Table 2. Summary of statements on DCS and PFO.
Supplementary Table 3. Classification of DCS.
Supplementary Table 4. Primary measures for secondary prevention of DCS.
Supplementary Table 5. Summary of statements on migraine and PFO.
Supplementary Table 6. GRADE evaluation of certitude of effects - studies on PFO closure for migraine prevention.
Supplementary Table 7. Summary of PICO question on migraine treatment.
Supplementary Table 8. Detailed PICO question for therapy of migraine.
Supplementary Table 9. Characteristics of the studies on PFO closure for migraine.
Supplementary Table 10. Diseases in which PFO can contribute to arterial hypoxaemia and its clinical consequences.
Supplementary Table 11. Summary of statements on arterial deoxygenation and PFO.
Supplementary Table 12. Position statements on pregnancy and the pre-operative management of patients.
Supplementary Table 13. Position statements on neurosurgery in the sitting position.
Supplementary Table 14. GRADE evaluation of certitude of effects - DCS.
Supplementary Table 15. Studies on DCS in recreational divers.
Supplementary Table 16. Studies on DCS in professional divers.
Supplementary Table 17. GRADE evaluation of certitude of effects - desaturation syndromes.

The supplementary data are published online at: https://eurointervention.pcronline.com/ doi/10.4244/EIJ-D-20-00785
Supplementary data

Supplementary Appendix 1. Methods

A detailed review of the methodology used can be found in the appendix of the previously published first part of this position paper [1].

In brief, grading of recommendations assessment, development, and evaluation (GRADE) methodology (http://gdt.guidelinedevelopment.org/app/handbook/handbook.html) was used to develop patient-intervention-comparator-outcome (PICO) questions, evaluate the evidence and formulate position statements. However, additional non-PICO questions were developed when there was a lack of clear evidence.

In June 2019, the evidence-synthesis team performed an additional update, beyond the original searches performed for the first part of the manuscript (databases searched: PubMed, Scopus, Google Scholar and ISI).

Evidence was evaluated qualitatively and, where possible, by quantitative methods. Quality of evidence was evaluated by means of the GRADE-PRO GDT online tool (https://gradepro.org) and graded accordingly as high, moderate, low or very low.

Two original meta-analyses were undertaken for the PICO question regarding migraine and for the non-PICO topic regarding arterial desaturation syndromes, because quantitative absolute risk reduction, normally performed with the GRADE method, was not deemed sufficient to formulate position statements.

The process of approval of the final version of this document by the task force, the EAPCI Scientific Documents and Initiatives Committee and by the Scientific Affairs Committee of the European Society of Cardiology was completed on April 14th 2020 and the paper submitted for publication on June 13th 2020.

Formulation of the PICO questions was performed as described in detail in the first part of this document [1]. While initiating the process of writing the first part of this document, the question regarding the treatment of migraine was classified as non-PICO. However, after the 2019 evidence evaluation update, it was clear that new data had been published, rendering it possible to transform it into a PICO question for this second part.

Position statements were formulated by consensus among the members of the task force.

Position statements were expressed evaluating the relevant outcomes in each particular setting. Before the systematic literature reviews, task force members formally defined outcomes for each question, grading their importance for making a decision regarding the position statements. Details regarding the methods used to grade the outcomes and the final grading of outcomes have been provided elsewhere [1].

Tables summarising the position statements indicate the strength of the position statement – strong or conditional (depending on patient values, physician opinion, resources available or setting) according
to the GRADE method. We also indicated the quality of the data: A) data derived from multiple RCTs or meta-analyses; B) data derived from a single RCT or large non-randomised studies; C) consensus of opinion of experts and/or small studies, retrospective studies and registries.

PICO and non-PICO questions underwent the process described above for developing position statements, all of which were finally incorporated into the various sections of the position paper.

**PICO and non-PICO questions**

1. Should percutaneous closure of a PFO versus diving avoidance be used for secondary prevention of decompression sickness in professional divers?
2. Should percutaneous closure of a PFO versus diving avoidance be used for secondary prevention of decompression sickness in recreational divers?
3. Should percutaneous closure of a PFO versus flying avoidance be used for secondary prevention of decompression sickness or asymptomatic embolisation in airplane pilots?
4. Should percutaneous closure of a PFO versus diving avoidance be used for primary prevention of decompression sickness in professional divers?
5. Should percutaneous closure of a PFO versus diving avoidance be used for primary prevention of decompression sickness in recreational divers?
6. Should percutaneous closure of a PFO versus flying avoidance be used for primary prevention of decompression sickness in airplane pilots?
7. Should percutaneous closure of a PFO versus medical therapy be used for platypnoea-orthodeoxia syndrome?
8. Should percutaneous closure of a PFO + medical therapy versus medical therapy alone be used for migraine? (slightly modified from the question previously adopted in the first part of this position paper) (PICO QUESTION)
9. Should percutaneous closure of a PFO versus no therapy be used in patients scheduled for surgery in a sitting position?
10. Should percutaneous closure of a PFO versus medical therapy be used for pregnant women with indications for the secondary prevention of stroke or other left-circulation thromboembolism?

**Literature search queries**

3. Should percutaneous closure of a PFO versus flying avoidance be used for secondary prevention of decompression sickness or asymptomatic embolisation in airplane pilots? ([decompression] or [sickness] or [airplane] or [pilot] or [fighter]) and ([pfo] OR [patent foramen ovale]) NOT ([review[pt] OR editorial[pt] OR letter[pt]])
4. Should percutaneous closure of a PFO versus diving avoidance be used for primary prevention in professional divers?

((decompression) or [sickness] or [airplane] or [pilot] or [fighter]) and ((pfo) OR [patent foramen ovale]) NOT ((review[pt] OR editorial[pt] OR letter[pt]))

5. Should percutaneous closure of a PFO versus diving avoidance be used for primary prevention in recreational divers?

((decompression) or [sickness] or [professional] or [recreational] or [amateur] or [divers] or [diver] or [scuba diving]) and ((pfo) OR [patent foramen ovale]) NOT ((review[pt] OR editorial[pt] OR letter[pt]))

6. Should percutaneous closure of a PFO versus flying avoidance be used for primary prevention in airplane pilots?

((decompression) or [sickness] or [airplane] or [pilot] or [fighter]) and ((pfo) OR [patent foramen ovale]) NOT ((review[pt] OR editorial[pt] OR letter[pt]))

7. Should percutaneous closure of a PFO vs medical therapy be used for platypnoea-orthodeoxia syndrome?

((platypnoea) OR [orthodeoxia] or [platypnoea-orthodeoxia syndrome]) and ((pfo) OR [patent foramen ovale]) NOT ((review[pt] OR editorial[pt] OR letter[pt]))

8. Should percutaneous closure of a PFO + medical therapy versus medical therapy alone be used for migraine with aura?


9. Should percutaneous closure of a PFO versus no therapy be used in patients scheduled for surgery in the sitting position?

([sitting] or [sitting position] or [semi-sitting position]) and ((pfo)OR [patent foramen ovale]) NOT ((review[pt] OR editorial[pt] OR letter[pt]))

10. Should percutaneous closure of a PFO versus medical therapy be used for pregnant women with indications for secondary prevention for left circulation embolism?


**Statistical methods, systematic review of evidence, assessment of its quality and meta-analyses**

Continuous variables are reported as means (standard deviation) or medians (range). Categorical variables are expressed as n/N (%).

Two original meta-analyses were performed for PICO and non-PICO questions. Statistical pooling was performed according to a random-effects model with generic inverse-variance weighting, computing risk estimates with 95% confidence intervals, using RevMan version 5.3 (The Cochrane Collaboration, The Nordic Cochrane Centre, and Copenhagen, Denmark, http://community.cochrane.org/tools/review-production-tools/revman). Hypothesis testing for superiority was set at the two-tailed 0.05 level. Hypothesis testing for statistical homogeneity was set at the two-tailed 0.10 level and based on the Cochran Q test, with I² values of 25%, 50%, and 75% representing, respectively, mild, moderate, and extensive statistical inconsistency.

A systematic review of evidence was performed for each question. PRISMA diagrams were produced to display the selection of the main searches. PRISMA diagrams were not produced for those questions that yielded a low number of publications.
High-quality evidence is generally lacking for PFO-associated syndromes. An evaluation of the quality of evidence was formally performed with the GRADE method for the meta-analyses performed to achieve the aims of this document.

We performed two meta-analyses aimed at assessing: a) the association of right-to-left shunt and decompression sickness, and b) the efficacy of PFO closure on desaturation syndromes. We also performed an original meta-analysis for supporting decisions on the PICO question on the treatment of migraine with PFO.

**Supplementary Figure 6, Supplementary Figure 7 and Supplementary Table 14**, respectively, display the PRISMA diagrams and the GRADE evaluation of the quality of evidence of the studies included in the meta-analysis assessing the association of right-to-left shunt and decompression sickness. **Supplementary Table 15**, and **Supplementary Table 16** display the studies included in the above-mentioned meta-analysis and in the review of studies involving decompression sickness.

**Supplementary Figure 8 and Supplementary Table 17**, respectively, display the PRISMA diagram and the GRADE evaluation of the quality of evidence of the meta-analysis of the studies assessing the efficacy of PFO closure on desaturation syndromes.

**Supplementary Figure 9, Supplementary Table 6, and Supplementary Table 9**, respectively, display the PRISMA diagram, the GRADE evaluation of the quality of evidence of the studies included in the meta-analysis and the characteristics of the studies comparing PFO closure plus medical therapies with medical therapies only for prevention of migraine in patients with migraine and PFO.

The main results of these meta-analyses are displayed in the published text.

**Supplementary Appendix 2. Detailed evaluation of specific issues**

**Decompression sickness pathophysiology and epidemiology**

Decompression sickness (DCS) is a complex condition caused by exposure to a hypobaric environment (“decompression”), such as flying at <350 mmHg barometric pressure or >18,000 ft altitude (altitude DCS) or returning to sea level after an ascent from depth (mining or diving). The fall in environmental pressure normally causes a reduction in partial pressure of inspired inert gases (mainly nitrogen), which then diffuse from the tissues where they were dissolved at higher partial pressures and are carried by the blood to the lungs, where they are expired. Even under normal conditions, vascular gas emboli (VGE) frequently form at this stage [124,125], but DCS occurs only if certain local and general conditions are met, where bubbles may be trapped locally, occluding post-capillary venous vessels and/or compressing adjacent tissues and triggering inflammation and thrombosis [126]. If a structural or functional R-T-L shunt is present [127], bubbles can also be arterialised and, according to their size, also trapped in small arteries or arterioles [128–130]. Small emboli may cause subclinical lesions, with still unknown late consequences [5–9].

The calculation of the actual risk of DCS during diving cannot be accurately estimated because accident data mostly stem from private dive insurance records, with clear selection bias, and because of reporting bias due to sometimes evanescent symptoms. Moreover, there are no data on the total number
of dives performed, except for certain isolated dive regions. In fact, while the risk of DCS has been estimated as being from 1 to 3 per 10,000 dives [126,131], an incidence of approximately 1.5% has also been reported [10]. In contrast, the frequency of severe altitude DCS appears to be lower and overall decreasing over time, mainly due to protective systems (e.g., cabin pressurisation), and the compressive effects of descent from altitude. However, in a survey of high-altitude military pilots performing frequent, long sorties (i.e., typically >9 hours per flight at >70,000 ft with <35 mmHg of barometric pressure), approximately 70% reported at least one episode of DCS during their career and, of those, 12.7% were severe enough for them to alter their flight plan or abort the mission [15]. The most recent evaluation of DCS risk per high-altitude flight in U2 aircraft pilots was 0.23%, and the incidence and severity of DCS, including life-threatening and permanent disability, were reported to increase with the number of missions [16,17].

The link between reported DCS events in high-altitude military pilots and PFO has yet to be established; however, the risk of DCS is more than theoretical for altitude greater than 18,000 ft. While altitude DCS is rare for exposures to altitudes between 18,000 ft and 25,000 ft, most cases occur among individuals exposed to altitudes of 25,000 ft or higher. The prevalence of DCS is influenced also by a series of conditions able to increase the risk: repetitive exposures to altitudes above 18,000 ft within a short period of time, rate of ascent to altitude, duration of the exposure to altitudes, physical activity, adequate period of denitrogenation, previous injury, ambient temperature, age, scuba diving before flying.

An intermediate risk could be acknowledged for high performance aircraft military pilots (F 22, Typhoon, etc.). They are exposed at high altitude (cabin pressure equivalent about 25,000 ft, at the ceiling altitude) but for a shorter period of time than U2 pilots. The anti G straining manoeuvre, very similar to a Valsalva manoeuvre, is frequently performed by pilots of aerotactical aircraft and it could increase the risk of DCS due to R-T-L shunt. However, altitude DCS is typically resolved during descent to a lower altitude while breathing 100% oxygen.

The risk for DCS remains negligible for commercial aircraft pilots. In fact, the typical cruising altitude for commercial aircraft is in the range 11,000–12,200 m (36,000–40,000 ft), and the air pressure in the cabin is equivalent to the outside air pressure at 1,800–2,400 m (6,000–8,000 ft) above sea level. The hypobaric environment below 2,500 m (8,200 ft) is usually well tolerated by healthy individuals. The possibility for altitude DCS remains for accidents (malfunctioning of pressurisation, canopy seal, bullets or objects hitting, etc.). However, accidental depressurisation is rare, often slow, and usually it does not affect aircrew health. Rates have decreased dramatically since the 1980s [132].

Training activity for aircrew in a hypobaric chamber is a typical controlled exposure to high altitude (>18,000 ft for a short period of time), that has been carried out for many years now. Reports from training centres show a very low prevalence or absence of DCS [133,134]. Even in these cases of altitude DCS, a clear relationship between index events and PFO presence is still lacking.

Is PFO associated with decompression sickness? Which are the underlying mechanisms?

The incidence of DCS is much lower in both divers and aircrews [27] than the prevalence of PFO in the general population [135]. A higher than normal prevalence of PFO in divers with DCS has been reported, especially with neurological symptoms [12,13,136], inner-ear DCS [11,138,139] and cutaneous DCS [14], particularly cutis marmorata [14,23,139].
A few prospective reports have also revealed a statistically significant association between PFO and white-matter lesions on MRI in military aircraft pilots [140] and in divers [9], but this was not confirmed by another report [141]. Moreover, arterial gas bubbles have been observed more frequently in divers with PFO than in those without PFO [142,143].

The association between risk of DCS and PFO has been estimated in retrospective, case-control studies only, with an OR of approximately 2.5 in a grouped analysis of recreational, military and professional divers [131]. In some studies analysing recreational divers performing provocative diving that requires decompression stops, a fivefold to sixfold risk increase in DCS was reported in divers with versus those without PFO [144,145].

We performed a meta-analysis of four correlation studies comparing the prevalence of R-T-L shunts in patients with and without DCS, and identified an OR of 5.63 (95% CI: 3.14-10.09) for R-T-L shunts in patients with DCS [11–14], albeit with moderate inconsistency between studies ($\chi^2$=25.15, p=0.004; I²=72%) (Supplementary Figure 1). The observed inconsistencies can be due to false negative results in diagnostic tests for PFO [3,26] (see the previously published section “thrombotic left circulation embolism” [1,2]) and other factors, such as the different types of ascent performed, the size of the PFO [146], and the definition of DCS used [147].

A PFO can play a role in DCS with different, alternative or simultaneous processes of paradoxical gaseous embolisation. Large PFOs with basal R-T-L shunts can also facilitate the process at rest [3,4]. As PFOs may increase their patency over time, this may contribute to the age-dependent vulnerability to DCS observed in some subjects [148]. However, paradoxical embolisation can also occur with smaller PFOs, when a 15-20% rise in right heart pressures, due to the trapping of VGE in the pulmonary arterial vasculature, causes their prolonged opening after 20-30 minutes [149]. This process may be summed to the elevation in right chamber pressures induced by certain common straining manoeuvres or isometric exercises performed by the divers during the decompression phase, such as climbing a vertical ladder while wearing full diving gear [150], or by military high-performance aircraft pilots during antigravity straining manoeuvres.

Is it clinically possible to estimate the probability of a causal relationship between a PFO and decompression sickness?

Studies on PFO-associated DCS remain lacking and considerations can only be based on reports. Therefore, any estimate of the causal role of a PFO should be made on a case-by-case basis.

PFO-associated DCS often has an early onset, occurring even during the ascent phase in cases of a frequently open or large R-T-L shunt, or after 20-30 minutes in cases of small or less frequently open PFO, needing the peak of VGE to cause any increase in right heart pressure. Moreover, symptoms have often been reported to be neurologic (including high-spinal, vestibular, cochlear, visual and cerebellar symptoms), because of the arterialisation of VGE [11–13,136]. More controversial is the link with DCS symptoms caused by lesions in the lower third of the spinal cord, because no clear VGE “pathway” can be proposed [3,12]. Cutis marmorata has been reported to be a sensitive sign of cerebral involvement in PFO-related DCS, especially if it occurs in divers after deeper, repetitive or multi-day diving [14,23,139].
A physical isometric effort or Valsalva (-like) manoeuvre immediately preceding the onset of symptoms is highly suggestive of a causative PFO. The same applies if symptoms occur after low-risk flights, such as those at low cabin altitudes or at high altitudes but for a short time, or dives such as those that are close to the limits of “no-decompression diving” or close to the required mandatory decompression stops, according to the utilised decompression model.

As previously stated, large PFOs also have a higher probability of having a causal role in DCS.

In dive or flight profiles likely causing high bubble loads, the role of intrapulmonary R-T-L shunts should be considered, due to the opening of functional arteriovenous shunts [127].

An association between PFOs and silent brain white-matter lesions on MRI has been suggested, but unreported clinical episodes of DCS might also be the cause of neurological lesions [151-154].

**What is the risk (and mechanism) of event recurrence with PFO-associated DCS?**

The main issue affecting recurrent DCS is the relationship between dive or flight characteristics and: a) the physiological characteristics that regulate tissue saturation with inert gases and their release; and b) factors that influence the threshold of “VGE tolerance” for DCS occurrence (i.e., the rate of VGE arterialisation and/or VGE trapping in tissues). These factors can both be variable (i.e., functional) or structural (e.g., PFO). Variable factors imply that similar dive/flight profiles can cause different loads of VGE, rendering DCS also possible with profiles classified as low risk if they are present. However, a PFO can also influence the threshold for “VGE tolerance” with a tendency for earlier and more abundant arterialisation during decompression. Therefore, one can assume that, while similar dive/flight profiles may cause different DCS occurrences in different individuals, in the same individual dives or flights with a similar risk profile have a similar risk of DCS [27].

Two studies have shown that, in professional divers who suffer PFO-associated DCS, the size of the PFO is a predictor of recurrence [21,22].

**Diagnosis of DCS**

The diagnosis of DCS is based on symptoms, the history of a dive or flight, and the apparent absence of other causal factors. Usually the first manifestations start within two hours of the beginning of decompression, but can also present after 1-2 days, especially if further reductions in environmental pressure happen within that time frame [126]. Symptoms of DCS have traditionally been classified as “minor” or “major” (Type I and Type II decompression sickness) (Supplementary Table 3), but these are not directly dependent on the profile of dives or flights. Mild cutaneous, visual or inner ear (vertigo) symptoms may often disappear spontaneously over the course of a few hours or days and should be enquired for. Physical activities or a Valsalva manoeuvre can immediately precede the onset of DCS [26].

Barotrauma of alveoli can lead to arterial embolisation of gas bubbles [155,156] and can mimic DCS, particularly if cerebral or high-spinal symptoms occur within minutes after surfacing from a dive [157]. This can happen: in rapid decompressions (e.g., explosive decompression in aircrews [132,158] and panic ascent without expiring during diving even in very short and shallow dives with compressed gas [159]; or in the presence of airway narrowing or focal stenosis (e.g., by mucous plugs) of pulmonary blebs or bullae during gradual, controlled ascents [155,156,160,161]. Therefore, high-resolution CT
scanning [162] and pulmonary function testing, including bronchial provocation testing, should always be performed [3].

VGE detected by echocardiography in patients with suspected DCS reinforces the diagnosis, because VGE grade is correlated to the risk of DCS [24].

White-matter lesions on MRI are traditionally considered the consequence of cerebral embolisation of decompression bubbles – although this view has recently been challenged [18,19].

**Secondary prevention**

Secondary prevention should primarily correct those factors that may have caused abnormal VGE production in each particular patient; modifying the patient’s lifestyle and “diving hygiene” is often needed (ceasing smoking or alcohol consumption, losing weight; ensuring adequate hydration before and after the dive/flight).

In addition, VGE formation can be prevented by reducing the inert gas saturation of tissues before decompression. Divers commonly use “decompression computers” which allow most recreational dives to be performed at low risk of DCS, especially if the dives are performed within the “no-decompression limit” (NDL). This means that the inert gas saturation (as calculated by the dive computer) at the end of the dive is not yet so high that mandatory “decompression stops” are needed during the ascent phase of the dive. However, there is epidemiological evidence that dives needing decompression stops are at a higher risk of DCS [126]. Consequently, if recommendations for recreational diving generally recommend low-risk “no-decompression dives”, this becomes mandatory in secondary prevention. Additional preventive measures include, for divers: reducing the frequency of dives, increasing the surface interval between dives, or using oxygen-enriched air (“nitrox”) to reduce the inert gas component of the breathing gas (for the same diving depth, extra safety is achieved if the computer is left on “air setting”); for aircrews: operational limitation on conventional aircraft; for both, controlling temperature during the dive/flight [28,29,36]. In recreational divers, counselling on conservative dive profiles was found to reduce the risk of DCS from 71.6/10,000 dives to 0/10,000 after a 5.3-year evaluation period in subjects with a large PFO and from 41.3/10,000 to 1.4/10,000 dives in those without a PFO [28]. In another study, “no-decompression” recreational diving reduced venous VGE by 50-80%, and arterialisation by 75-100% in divers with a large PFO [29].

Regarding PFO closure, one prospective study in 104 divers with previous DCS uncovered a statistically significant reduction in symptomatic and asymptomatic (as assessed by MRI) DCS recurrence over five years in patients who chose to have their PFO closed, compared to those who did not, yielding a risk of “major DCS” of 0.5/10,000 dives and 35.8/10,000 dives, respectively [5]. It appears that the divers who did not have their PFO closed did not substantially change their diving behaviours. However, the number of subjects was low and there was significant dropout.

Some case reports have been published on divers who suffered recurrent DCS after PFO closure [33–35]. Although a residual shunt was detected in some of these patients, it is possible that, in others, a provocative dive profile caused high VGE loads, resulting in recurrent DCS, even with a successfully closed PFO.
The joint international position paper of underwater medicine societies’ statements regarding PFO and diving are the following [30]:

1. Routine screening of divers for the presence of PFO is not recommended
2. Suspect PFO if there were one or more episodes of cerebral, spinal, vestibular or cutaneous DCS
3. PFO testing should be performed using contrast TTE; with provocation manoeuvre and in centres with experience in performing the test
4. When interpreting a positive testing result: consider size and degree of patency (spontaneous or only after provocation manoeuvre) of PFO versus smaller shunts, and the clinical/diving context of DCS. A definite causal relation between the PFO and the DCS episode is not always possible to ascertain.
5. PFO treatment options are
   A. Stop diving
   B. Dive more conservatively
   C. Percutaneous closure
6. When considering these options, careful consideration is needed of the risks and benefits and the clinical considerations that led to the screening
7. Return to unrestricted diving after PFO closure only if:
   A. Closure is confirmed with repeated contrast echo >3 months after procedure
   B. Potent antiplatelet medication is stopped (aspirin is OK)

Is a primary screening or prevention advised?
There are neither prospective observational studies nor randomised controlled clinical trials available in support of routine screening or closure of a PFO for the primary prevention of DCS. Indeed, DCS also remains an infrequent event in individuals with a PFO and there is agreement across diving medicine societies worldwide [30,36] that primary screening for PFO should not be done in recreational divers on a routine basis, because of an unfavourable cost-effectiveness ratio. The same applies for professional divers and conventional altitude pilots, because the risk of DCS in these groups is very low [37], and, even when a R-T-L shunt is present, arterialisation of VGE does not always take place [38].

Some diving medicine societies suggest considering primary screening for PFO in any diver with “high-risk” conditions — such as other congenital heart disease, a family history of atrial septal defects, or a history of migraine with aura or cryptogenic stroke — but little or no evidence supporting this choice is available [30].

Migraine
Migraine can be preceded by an aura with transient visual, verbal, or somatosensory symptoms and can result in significant impairment in daily activities, especially in chronic forms. The most plausible electrophysiological substrate of headaches and aura symptoms is cortical spreading depression (CSD) [61,62].

Is PFO associated with migraine? What are the underlying mechanisms?
The association between PFOs and migraine is supported by a higher prevalence of PFO in migraineurs than in the general population, as observed in several studies [44–47] and, in a meta-analysis, especially in those with auras [48]. Moreover, the high prevalence of migraine attacks in some inherited disorders — like hereditary haemorrhagic telangiectasia — where atrial or pulmonary shunts exist [54,55], stands as indirect evidence of a pathogenic role of a right-to-left shunt. Another source of evidence of the association between PFOs and migraine is the finding of incidental improvement in migraine attacks in patients who undergo percutaneous closure of a PFO for other reasons [52].

However, the association between migraine and PFOs is likely to vary across heterogeneous populations, as other studies have failed to identify such an association [56–60], especially when patients with specific subgroup characteristics were considered [60,69]. A direct link between PFOs and auras rather than headaches has also been hypothesised [46]. In some studies, PFO closure was associated with a dramatic increase in migraine in certain patient subgroups [163,164].

Potential pathophysiological mechanisms include paradoxical cerebral thromboembolism [47,63] which can trigger attacks through focal ischaemia causing a cortical spread depression [61,64–66] and/or the direct passage of metabolites like serotonin or other vasoactive substances to the systemic circulation (also possibly released by platelets activated by shear stress in the PFO), resulting in irritation of the trigeminal nerve and the brain’s vascular network [67,68].

**Is it clinically possible to estimate the probability of a causal relationship between a PFO and migraine?**

In some studies, the number of bubbles crossing the PFO, detected by c-TCD, has correlated with the severity and frequency of attacks in migraineurs with auras [52,64]. A subpopulation where the association between PFOs and migraine was particularly evident was patients with a previous stroke [47]. Moreover, patients with a history of subclinical brain lesions or a cryptogenic ischaemic event appeared to benefit from PFO closure, in terms of the frequency and severity of migraine attacks, more than patients without cerebrovascular disease [71,72]. Additionally, a trend towards a higher prevalence of right-to-left shunt with larger-size PFOs in subjects with migraine with aura has been reported [60].

In two studies, older age seemed to be associated with an absence of relationship between PFOs and migraine [59,60]; however, other studies did not support an association between the frequency of migraine attacks and PFO characteristics [56–58].

**Treatment**

*Additional insights on the safety and efficacy of percutaneous closure*

The MIST trial was published in 2008 as the first double-blind, randomised trial comparing PFO closure versus non-closure in patients with migraine [73]. It evaluated PFO closure with the STARFlex® septal repair implant (NMT Medical Inc., Boston, MA, USA) against a sham intervention in 147 patients (74 assigned to the device group and 73 to the sham procedure). Patients had to be 18 to 60 years of age and have a history of migraine with auras, as defined by the criteria of the International Headache Society, all starting before 50 years of age. They also had to have >5 migraine headache days per month, but at least 7 headache-free days per month; and report having failed at least two classes of
preventative medication because of inefficacy or intolerability, as judged by an investigator. The primary efficacy endpoint was cessation of migraine headache 91 to 180 days after the procedure. No significant difference was observed in the primary endpoint of migraine headache cessation between the implant and sham groups (3 of 74 versus 3 of 73, respectively; \( p=0.51 \)).

In the main paper, the authors reported that there were 37.7% of patients with a right-to-left shunt attributed to large or moderately large PFO; however, this finding has been a source of dispute because subsequently it was shown that intrapulmonary shunts were erroneously attributed to intracardiac shunts [165]. Furthermore, all the results and how the study was conducted were contested, with two researchers even refusing to sign the final paper [165]. As a consequence, an erratum was published, including a new version of supplements and the paper [166]. The principal investigator of the study was subsequently found guilty of misconduct in this research, including dishonesty, and suspended from the Medical Register [167]. In any case, even considering the published data, the study suffered severe limitations which included an undersized sample, use of a device which is now off the market, and less than optimal primary efficacy after implantation.

The PRIMA trial [74] compared PFO closure with the AMPLATZER™ PFO Occluder (St. Jude Medical, St. Paul, MN, USA) against medical management. This study had a six-year enrolment period and was prematurely stopped by the sponsor at 89% of the foreseen sample size, because of the slow enrolment rate. Ultimately, 107 patients had been randomised 1:1 to percutaneous PFO closure or medical management (53 to device therapy and 54 to medical therapy) with stratification by gender and age, across 20 centres. Of the total, 99% of the patients had migraine with aura. Patients were eligible if their migraine appeared before 50 years of age, if, over a three-month baseline period, they experienced either a minimum of three migraine attacks or five migraine headache days per month with 15 headache days per month and if they had been unresponsive to two commonly applied preventative medications. The primary endpoint was reduction in monthly migraine days during months 9–12 after randomisation compared with the three-month baseline period before randomisation. At six months, 88% of patients in the device therapy arm had the PFO successfully closed, as indicated by tranoesophageal echocardiography (TOE).

At one year, a similar number of primary endpoint events was observed in the PFO closure group when compared with the control group (22.9 vs 21.7 days; \( p=0.17 \)). In the PFO closure group, 38% of patients experienced a 50% or greater reduction in the number of migraine days relative to baseline compared with 15% in the control group (\( p=0.0189 \)). However, the number of migraine attacks was similar in the PFO closure and control groups (22.1 vs 21.3; \( p=0.097 \)). Post hoc analysis revealed a greater mean reduction in migraine with aura days per month and in the number of migraine attacks with aura in the PFO closure group versus the control group (22.4 vs 20.6 days; \( p=0.0141 \) and 22.0 vs 20.5; \( p=0.0003 \), respectively). A complete remission of migraine was observed in 10% of patients, all of these after PFO closure. There were six serious adverse events in the PFO closure group, all without long-term sequelae. Limitations of this study include the lack of blinding, underpowering of the study, lower than anticipated patient retention, and a 12% rate of incomplete closure in the device arm at six months.

The PREMIUM trial [75] compared PFO closure with the AMPLATZER PFO Occluder against medical management with a sham procedure (right heart catheterisation). The study had a seven-year enrolment phase, during which 230 patients were enrolled and randomised: 123 subjects randomised to the active device group and 107 to the control group. Subjects had 6 to 14 days of migraine per month, had failed at least three migraine-preventative medications, and had a significant right-to-left shunt
defined by transcranial Doppler. Sixty-five percent had migraine with aura and 20% had an atrial septal aneurysm. Primary endpoints were responder rate, defined as a 50% reduction in migraine attacks, and adverse events. Secondary endpoints included reduction in migraine days and efficacy in patients with versus without aura.

Adequate closure of the PFO at one year (<30 bubbles in one minute on transcranial Doppler) was obtained in 83% of patients randomised to device therapy. At one year, 78 primary efficacy events and one safety endpoint were adjudicated. The responder rate was similar in the two groups (45/117 in the device group and 33/103 in controls); however, device implantation significantly reduced the number of migraine with aura days (p<0.01) and attacks (p<0.01), and only after PFO closure did 8.5% of patients experience complete remission of migraine over a one-year time period. Furthermore, on post hoc analysis of trial data, patients with frequent attacks with aura had a statistically significant reduction in the primary outcome relative to controls (49% vs 23%, p<0.04). The main limitation of the study was the undersized sample (in the control group the risk was 50% lower than foreseen).

Two trials (MIST II and ESCAPE) were cancelled by their sponsors shortly after the beginning of enrolment.

Arterial desaturation syndromes

In one study, up to 30% of patients with a PFO were discovered to have clinically significant arterial deoxygenation during effort [79], suggesting that this situation might be more frequent than previously hypothesised [168]. Two case-control studies have identified a higher incidence of PFO in patients with obstructive sleep apnoea syndrome (OSAS) than in healthy controls [169,170], while two others revealed a correlation between hypoxaemia and PFO characteristics [169,171]. Among patients with COPD, several studies have shown a higher prevalence of PFO than in normal populations [86,172–175]; however, a correlation with hypoxaemia was not confirmed by all studies [175]. With high-altitude pulmonary oedema (HAPO), linked to hypoxaemia, an association with PFO was hypothesised in even fewer observational studies [176], although the hypoxaemia correlated with PFO characteristics in a small, preliminary observational study [177].

Can PFO be associated with arterial hypoxaemia? What are the underlying mechanisms?

Even though the shunt through a PFO is usually haemodynamically trivial, under certain conditions the right-to-left shunt causes clinically significant arterial deoxygenation by mixing venous and arterial blood. The shunt, and the consequent hypoxaemia, can be transient or persistent, depending upon the underlying mechanisms and anatomical characteristics. The longer the shunt is flowing during the cardiac cycle and the larger the shunt’s volume, the more severe the arterial hypoxaemia is. The most important circumstance associated with this is pulmonary arterial hypertension, which may cause right heart chamber pressures to rise, the trans-PFO gradient to increase and, consequently, also the right-to-left shunt grade. However, anatomic factors such as a large Eustachian valve directed towards the PFO and/or deformation of the atria and the septum may cause high localised haemodynamic pressure just around the fossa ovalis, which is capable of generating a significant shunt even in the presence of normal mean right atrial pressure.
**Treatment**

In platypnoea-orthodeoxia syndrome (POS) due to PFO, the evidence for percutaneous closure is based upon case reports, case series and only two small registries, because of its rarity. Three small series revealed stable relief of symptoms up to five years post closure, with improved standing arterial oxygen saturation in all patients without severe pulmonary hypertension [81–83]. Two larger registries on 128 patients overall confirmed these results with a 6% incidence of procedure-related complications [84,85]. In all these studies, the persistence of dyspnoea at follow-up, mainly exertional, was due to incompletely evaluated underlying pulmonary disease upstream.

For OSAS, PFO closure has been described in case reports [168], all showing improved symptoms and decreased apnoeic episodes, and one case-control observational study involving 40 patients, which showed statistically significant improvements in indices of apnoea and desaturation episodes and a reduction in systemic arterial pressure and increased left ventricular diastolic function [86].

No data are available regarding PFO closure in COPD patients.

For exertional desaturation, only one cohort study with 14 patients has been reported on PFO closure (two surgical), in which statistically significant improvement in oxygen saturation (average increase of 10) and NYHA functional class (by a median of 1.5 classes) was observed after interventional therapy, relative to baseline [79].

For high-altitude pulmonary oedema (HAPO), only two reports describe the prevention of disease by percutaneous closure of PFO [178,179].

**Platypnoea-orthodeoxia**

**Definition of POS**

Platypnoea-orthodeoxia syndrome (POS) is a condition characterised by dyspnoea and arterial deoxygenation (SpO2 <90% or PO2 <60 mmHg), with or without cyanosis, induced by an upright position, and typically relieved by lying supine [180].

The syndrome is rarely diagnosed and its prevalence in the general population remains unknown [84,181]. Three main pathophysiological processes, in various combinations, may lead to this syndrome: intracardiac shunts (cardiac POS syndrome), pulmonary arteriovenous shunts, and ventilation/perfusion mismatch [182].

The most common aetiologic association is an interatrial right-to-left shunt through a PFO [183], an atrial septal defect (ASD), or a fenestrated atrial septal aneurysm (ASA). Considering the prevalence of PFOs in the adult population (close to 25%), it may be that POS occurs more frequently than has been reported in the literature.

Right-to-left interatrial shunting is usually associated with spontaneous or induced pulmonary hypertension. Right-to-left shunting with normal pulmonary artery pressure is uncommon. In the absence of pulmonary hypertension, other mechanisms might explain a right-to-left interatrial shunt and, consequently, the syndrome: for example, an interatrial pressure gradient, or preferential blood flow streaming from the inferior vena cava into the left atrium, through the PFO, even in the absence of an interatrial pressure gradient.
Even if an interatrial communication (PFO, ASD or fenestrated ASA) is necessary for cardiac POS, a prominent Eustachian valve and right chamber anatomy modification can act as contributing factors. Several mechanical conditions – mainly right diaphragmatic paralysis and ascension [184,185], kyphoscoliosis [186], restrictive lung disease, previous pneumonectomy [187–189], pleural effusion, and an ectasic/aneurysmal ascending aorta [190,191] – may lead to atrial chamber or septal deformity, thereby changing the anatomic relationship between the atrial septum and the inferior vena cava and, thus, facilitating desaturated blood flow redirection through the PFO.

**Diagnostic workup of POS**

The diagnosis of POS in patients presenting with respiratory symptoms is difficult, so that it is usually a “rule-out diagnosis”.

Desaturation is not exacerbated by exercise and is strikingly resistant to the inhalation of high-concentration oxygen.

The history of symptoms can be short; symptoms can emerge acutely, worsen rapidly and be progressive within a few days.

Patients with this syndrome may or may not have a decubitus preference (“trepopnoea”).

The initial assessment should be to document the association between dyspnoea and the upright position. Consequently, it is useful to demonstrate an association between oxygen desaturation (via blood gas analysis or pulse oximetry) and the patient being upright, even if 100% oxygen is administered.

Various investigations — including blood analysis, spirometry, pulmonary CT scan, pulmonary CT angiography, and a lung ventilation/perfusion scan — are useful to exclude non-cardiac causes of POS.

The imaging technique initially recommended to investigate intracardiac shunting disease is TTE with colour Doppler or after the intravenous injection of contrast (10 ml of a saline-agitated solution). The examination should be performed with the patient in both a lying and upright position and may allow demonstration of an interatrial communication, the right-to-left shunt (because of the passage of microbubbles to the left atrium in the first three beats after right cavity opacification) and the exclusion of pulmonary hypertension.

The diagnosis of POS due to interatrial communication is very difficult to establish using TTE, because the atrial septum is poorly visualised with TTE.

The simplest examination to determine the diagnosis is c-TOE, taken in the supine and sitting position, showing, either on colour Doppler or after the intravenous injection of contrast (10 ml of a saline-agitated solution), an atrial right-to-left shunt via the PFO, a small ASD, or a fenestrated ASA. In addition, TOE is useful to demonstrate the presence of underlying anatomical causes of the right-to-left shunt, such as a prominent Eustachian valve, deformed aortic root, aneurysmal expansion, or elongation of the ascending aorta.
The diagnosis can be confirmed on contrast TOE with simultaneous monitoring of the peripheral capillary oxygen saturation (SpO₂), which should clearly demonstrate concordance between a postural increase in right-to-left shunting and desaturation.

The gold standard cardiac test remains cardiac catheterisation. However, these measurements are not routinely performed, as a non-invasive workup (echocardiography and peripheral oxygen saturation measurements) is usually sufficient to establish the diagnosis, because patient disability rather than shunt magnitude dictates the decision for interatrial defect closure.

**Neurosurgery in the sitting position**

Despite the risks associated with operations conducted in patients in a sitting position, performed to approach the posterior fossa or dorsally located parietal lesions [102], and the dramatic decrease in operations in this position [101], many teams still adopt this strategy as a first choice because of its considerable advantages for patients [105–109].

Among the most dreadful complications associated with this position, venous air embolism after venous incision can occur in up to 50-79% of cases, depending on the sensitivity of the monitoring tool used [93,103,104], with severe immediate and delayed cardiopulmonary and cerebral complications [95–98]. In turn, these can cause paradoxical air embolisms in up to 14% of patients if a PFO is present [112–115]. The lower rate and the wide range (0-14%) in the overall reported incidence of paradoxical air embolism, relative to venous air embolism (VAE) at large, is probably primarily due to selection bias, but also to differences in monitoring tools, incomplete data registration, and heterogeneity within the populations of patients with PFO. For this reason, a PFO remains an absolute contraindication to surgery in the sitting position. Moreover, many surgeons routinely prefer other surgical positions [99,100], even though VAE [93] and hypotension [94] may also occur with patients in a lateral or prone position, and these can also cause serious additional hazards [110,111]. Nonetheless, if surgeons are aware of a PFO’s presence, neurosurgical operations can be carried out safely on patients with a PFO in a prone position, provided close monitoring is performed throughout the operation [116,117].

**Prevention and treatment**

**Perioperative monitoring**

Besides routine monitoring, continuous monitoring of end tidal CO₂ (ETCO₂) is used throughout the operation to detect clinically significant VAEs. ETCO₂, in combination with TOE, is used as the most sensitive parameter [118]. A sudden drop in the ETCO₂ level associated with hypotension is highly suggestive of air embolism [119]. Capnography is also a widely available diagnostic tool. An alternative method is the measurement of expired nitrogen [120].
Supplementary Figure 1. Meta-analysis of studies comparing the prevalence of R-T-L shunting in patients with and without DCS.
Supplementary Figure 2. Meta-analysis of observational and randomised trials regarding the incidence of persistent migraine comparing closure versus non-closure of PFO in studies with two cohorts.
**Supplementary Figure 3.** Meta-analysis of observational and randomised trials regarding the incidence of persistent migraine comparing closure versus non-closure of PFO in studies with two cohorts, by aura status.
**Supplementary Figure 4.** Meta-analysis of observational trials assessing persistence of migraine before and after PFO closure, by aura status.
Supplementary Figure 5. Meta-analysis of studies on PFO closure in desaturation syndromes.

Improvement in blood oxygen saturation after PFO closure.
Supplementary Figure 6. PRISMA diagram of decompression sickness studies in recreational divers.
Supplementary Figure 7. PRISMA diagram of decompression sickness studies in professional divers.
Supplementary Figure 8. PRISMA diagram of decompression sickness studies in desaturation syndromes.
Supplementary Figure 9. PRISMA diagram of migraine studies.
Supplementary Table 1. Characteristics for the evaluation of a probable causal link between a PFO and DCS.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Large size of the PFO [24,25]:</td>
<td>C</td>
</tr>
<tr>
<td>• Early onset of DCS during or after the ascent (with a large PFO)</td>
<td>C</td>
</tr>
<tr>
<td>• Onset of DCS 20-30 minutes after the ascent (with a small PFO)</td>
<td>C</td>
</tr>
<tr>
<td>• Neurological (high-spinal, vestibular, cochlear, visual and cerebellar)</td>
<td>C</td>
</tr>
<tr>
<td>symptoms [15-17,26]</td>
<td></td>
</tr>
<tr>
<td>• Cutis marmorata (in divers, after deep and/or repetitive dives) [18]</td>
<td>C</td>
</tr>
<tr>
<td>• History of any isometric effort shortly before DCS onset</td>
<td>C</td>
</tr>
<tr>
<td>• DCS onset after/during low-risk flights (low cabin altitude or high cabin</td>
<td>C</td>
</tr>
<tr>
<td>altitude for a short time)</td>
<td></td>
</tr>
<tr>
<td>• DCS after/during low-risk dives, close to no-decompression limits</td>
<td>C</td>
</tr>
<tr>
<td>• Dives or flights causing low bubble loads [27]:</td>
<td>C</td>
</tr>
</tbody>
</table>
### Supplementary Table 2. Summary of statements on DCS and PFO.

#### APPROACH TO DECOMPRESSION SICKNESS

<table>
<thead>
<tr>
<th>Position Statements</th>
<th>Strength of the statement</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>A secondary prevention work-up should be initiated only if a DCS diagnosis is</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>probable or if uncertainty regarding DCS is unacceptable for the individual risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>profile or patient's preference.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Individual risk stratification should consider clinical, anatomical and functional</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>neuroimaging and dive/flight profile data.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>In the same patient, the dive/flight profile relative to individual characteristics</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>is the main determinant of DCS.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>In cases of DCS during low-risk activities or activities with a high but non-</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>modifiable risk, PFO screening must be considered part of the diagnostic work-up</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decision making should be considering estimations of the patient’s: a) Probability</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>that the PFO has a causal role in the clinical picture b) Risk of recurrence (flight/diving habits and/or needs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The probability of simultaneous or alternative intrapulmonary shunts and/or of</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>pulmonary overpressure syndrome should always be considered.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shared decision making should be documented, accompanied by open, individualised,</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>informed consent.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### SECONDARY PREVENTION OF DECOMPRESSION SICKNESS

<table>
<thead>
<tr>
<th>Position Statements</th>
<th>Strength of the statement</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regardless of the presence of a PFO, secondary prevention should primarily be</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>aimed at suppressing VGE production, up to possible permanent cessation of the</td>
<td></td>
<td></td>
</tr>
<tr>
<td>activity (Supplementary Table 4).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFO closure can be offered to those patients having suffered from DCS: a) with a</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>high probability of causal PFO; b) when cessation of diving/flying is not an option;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>or c1) when it is not possible to achieve an effective behavioural change to prevent the production of venous gas emboli; or c2) when the risk of further DCS, despite conservative limitations, is deemed unacceptable by the patient after consultation with an experienced dive or aerospace physician.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prior to consideration of PFO closure, patients should be informed that this</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>procedure is expected to reduce the risk of paradoxical VGE but will have no effect on VGE or pulmonary shunts.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>In cases involving professional divers or pilots, offering PFO closure should be</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>balanced against the possible consequences of PFO closure on work activities,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>according to local and international regulations.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>In patients who have undergone PFO closure, documentation of complete closure of the PFO on follow-up is necessary for the patient to resume unrestricted diving.</td>
<td>Strong</td>
<td>C</td>
</tr>
</tbody>
</table>

#### PRIMARY PREVENTION OF DECOMPRESSION SICKNESS

<table>
<thead>
<tr>
<th>Position Statements</th>
<th>Strength of the statement</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary screening for PFO is not indicated on a routine basis in divers and/or</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>aircrews.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>When PFO is an incidental finding, no restrictions on conventional altitude flights are advisable for any person.</td>
<td>Strong</td>
<td>C</td>
</tr>
</tbody>
</table>
When PFO is an incidental finding in a recreational diver, the individual should be counselled by an experienced diving physician, according to the context, size of shunt, and the individual’s compliance/preferences.

<table>
<thead>
<tr>
<th>Conditional C</th>
<th>Conditional C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary PFO screening can be proposed to professional divers performing working activities with non-modifiable high-risk characteristics for DCS</td>
<td>Military pilots assigned to frequent and prolonged flight activity at &lt;280 mmHg barometric pressure or &gt;25,000 ft can undergo PFO screening according to local regulations</td>
</tr>
</tbody>
</table>

In an individual at very high risk for DCS for professional reasons, possible primary closure of the PFO must be evaluated in conjunction with the individual and an experienced diving or aerospace physician, considering job characteristics, individual clinical features, local/international work regulations, and patient’s preference.

**Supplementary Table 3. Classification of DCS (modified from Germonpré et al [23]).**

<table>
<thead>
<tr>
<th>Type I DCS</th>
<th>Type II DCS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Classification</strong></td>
<td>Non-systemic, peripheral, “minor”</td>
</tr>
<tr>
<td><strong>Symptoms and signs</strong></td>
<td>Pain</td>
</tr>
<tr>
<td></td>
<td>– Joint and tendon pain</td>
</tr>
<tr>
<td></td>
<td>Lymphatic</td>
</tr>
<tr>
<td></td>
<td>– Localised lymphatic congestion</td>
</tr>
<tr>
<td></td>
<td>Spinal</td>
</tr>
<tr>
<td></td>
<td>– Paralysis, paresis</td>
</tr>
<tr>
<td></td>
<td>Cutaneous symptoms</td>
</tr>
<tr>
<td></td>
<td>– Itching</td>
</tr>
<tr>
<td></td>
<td>– Rash</td>
</tr>
<tr>
<td></td>
<td>– Localised cyanosis</td>
</tr>
<tr>
<td></td>
<td>– Cutis marmorata</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Supplementary Table 4. Primary measures for secondary prevention of DCS.

<table>
<thead>
<tr>
<th>Measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Lifestyle and behavioural changes (stop smoking, stop alcohol consumption, lose weight, ensure adequate hydration)</td>
</tr>
<tr>
<td>• Provide temperature control during dive or flight</td>
</tr>
<tr>
<td>• <strong>For divers</strong> - Conservative diving profile [28]: No-decompression dives [29,30] and reducing the frequency of dives</td>
</tr>
<tr>
<td>• <strong>For aircrews</strong> - flying with operational limitation on conventional aircraft</td>
</tr>
<tr>
<td>• Breathing high concentrations of oxygen before the ascent (pre-breathing with 100% oxygen before and during the flight in aircrews and, in divers, oxygen-enriched gas mixes for underwater breathing using the “air” setting decompression profile on the computer)</td>
</tr>
</tbody>
</table>

Supplementary Table 5. Summary of statements on migraine and PFO.

<table>
<thead>
<tr>
<th>Position Statements</th>
<th>Strength of the statement</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>The association between migraine and PFO is supported by observational data, but it is variable across subpopulations and therefore in the clinical setting may be incidental</td>
<td>Strong</td>
<td>B</td>
</tr>
<tr>
<td>The clinical, anatomical and imaging characteristics of different subpopulations of patients with PFO-associated migraine have not been sufficiently assessed.</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>According to literature, factors that may suggest a pathogenic role of PFO in migraine are the presence of 1) an aura and 2) previous stroke; while older age and small shunts through the PFO would suggest a less likely causative relationship between a PFO and migraine.</td>
<td>Conditional</td>
<td>C</td>
</tr>
</tbody>
</table>
Supplementary Table 6. GRADE evaluation of the certitude of effects - studies on PFO closure for migraine prevention.

<table>
<thead>
<tr>
<th>certainty assessment</th>
<th>Nº of participants (studies) Follow-up</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Publication bias</th>
<th>Overall certainty of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCT</td>
<td>44g (3 RCTs)</td>
<td>Serious&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Serious&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Not serious</td>
<td>Serious&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Not serious</td>
<td>LOW</td>
</tr>
<tr>
<td>OBSERVATIONAL STUDIES</td>
<td>1460 (22 observational studies)</td>
<td>Serious&lt;sup&gt;d&lt;/sup&gt;</td>
<td>serious&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Not serious</td>
<td>Serious&lt;sup&gt;f&lt;/sup&gt;</td>
<td>Serious&lt;sup&gt;f&lt;/sup&gt;</td>
<td>VERY LOW</td>
</tr>
</tbody>
</table>

a. Due to different selection criteria among the studies, including high risk patients in 1/3 studies.
b. Due to different methods to assess migraine severity
c. Due to: 1) Different methods to assess migraine severity and b) heterogenous or not defined medical therapy for migraine
d. Risk of inclusion of “palliative” procedures
e. No data about medical therapy
f. Due to tendency to publish positive results
Supplementary Table 7. Summary of the PICO question on migraine treatment

In patients with migraine and PFO, should percutaneous closure of PFO vs. medical therapy be used for reduction of migraine?

**TYPE OF STATEMENT**

<table>
<thead>
<tr>
<th>Strong statement against the intervention</th>
<th>Conditional statement against the intervention</th>
<th>Conditional statement for either the intervention or the comparison</th>
<th>Conditional statement for the intervention</th>
<th>Strong statement for the intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>○</td>
<td>●</td>
<td>○</td>
<td>○</td>
<td>●</td>
</tr>
</tbody>
</table>

**CONCLUSIONS**

**Statement**

The position of our societies is that available data do not allow us to support interventional therapy as an alternative or as adjunct to medical therapy in patients with migraine, but new randomized studies should indeed be performed.

However, outside of specific trials, it is acceptable to propose percutaneous closure of a PFO, after an in-depth individual multidisciplinary evaluation, on a compassionate-use basis in the extreme cases of carefully selected patients suffering from migraine with aura and/or cerebrovascular disease who have a poor quality of life despite optimal medical therapy prescribed by migraine specialists. In this case, the role of the patient should be proactive, keeping in highest regard his/her values and preferences regarding outcomes and therapeutic trade-offs, and informing him/her about the uncertainties of their condition and available evidence.

Moreover, patients with migraine and previous cerebrovascular accident should be evaluated according the previously published position statements for systemic thromboembolism and treated for the prevention of this condition.

**Justification**

**Overall justification**

The last comprehensive meta-analysis of 3 RCTs and 22 observational studies in 1909 patients showed a statistically-significant advantage of PFO closure vs. medical therapy for improving migraine (Supplementary Appendix 2 – Supplementary Tables 6, 8 and 9). However, the certainty of these effects was very low, given that this evidence is only driven by observational studies and not by RCTs, which were all negative for the primary hypothesis. Nonetheless, two out of three RCTs showed superiority for some secondary outcome measures with PFO closure over medical therapy. Moreover, the benefit of percutaneous closure was clear in patients with aura or, in a previous meta-analysis of observational trials, we identified a statistically significant advantage for some secondary outcome measures with PFO closure over medical therapy. Moreover, the benefit of percutaneous closure was clear in patients with aura or, in a previous meta-analysis that incorporated a smaller number of patients, in those with cerebrovascular disease. The data supporting therapeutic efficacy in some subgroups underscores the heterogeneity of this population and the need to better characterise key features. Therefore, the weakness of the evidence accrued so far should still be considered only hypothesis-generating for future specifically targeted randomised studies.

Nonetheless, given the invalidating nature of the disease, the signal towards a benefit of PFO closure in patients with aura and cerebrovascular disease, the low incidence of undesirable effects with percutaneous closure, and the frequent preference of patients for therapies which have the potential to improve their poor quality of life regardless of the risks and side effects, percutaneous PFO closure may be proposed on a compassionate-use basis in patients with aura or cerebrovascular disease who are poor responders to maximal drug therapy, after a carefully-shared decision-making process involving migraine specialists and cardiologists and which must be tailored to the patient’s personal values and preferences.

**Detailed justification**

**Problem**

Migraine is a frequent and incapacitating disease in the population, despite medical treatments. Patients suffering from migraine, in the majority of cases, prefer any therapy which is effective, regardless of its risks and side effects. Therefore, the therapy of migraine is a priority and all potential solutions should be considered to relieve life-impairing pain.

**Desirable effects**

The 3 RCTs individually did not show any superiority of percutaneous closure of PFO over medical therapy at reducing the primary endpoint of the studies in disparate patient populations. The results of our meta-analysis of RCTs are also neutral. However, in the PRIMA and PREMIUM trials, statistically-significant improvements in the number and duration of attacks were reported (secondary endpoints - see Supplementary Appendix 2), showing that a benefit could be achieved, albeit not in the primary outcome[74,75]. These findings were confirmed by a previously published meta-analysis [77]. Furthermore, in our meta-analysis of observational trials, we identified a statistically significant reduction in migraine with PFO closure vs medical therapy (Supplementary Appendix 2 – Supplementary Table 8 and Supplementary Figures 2, 3 and 4).

**Undesirable effects**
The undesirable effects of both PFO closure and medical therapy have been inconsistently reported across studies. However, in our meta-analysis of RCTs, their incidence was low and most adverse effects were transient (0.5–1.1%).

**Certainty of evidence**

The certainty of evidence is severely questioned, since the main evidence stems from non-randomized studies or secondary endpoints of RCTs, with all inherent limitations of this kind of analyses. Moreover, several limitations of RCTs also make their interpretation problematic: e.g., ubiquitous under-sized studies, wide confidence intervals, high incidence of incomplete PFO closures, disparate selection criteria, and different PFO closure devices.

Specifically, in our meta-analysis, the certainty of the evidence was judged severely (Supplementary Tables 6 and 8).

Further adequately structured studies are, therefore, necessary to improve the certainty of evidence.

**Values**

No specific studies addressing values and preferences of patients have been performed for PFO-associated migraine. However, in patients with migraine at large, studies have shown that patients do have preferences in therapies, and they tend to prioritize the effectiveness of therapy for migraine over side effects and safety [192-196].

**Balance of effects**

In our meta-analysis, the incidence of undesirable effects was similar with drug and interventional therapy; therefore, in subjects in whom PFO closure is effective at improving migraine, the balance is in favor of interventional therapy.

**Acceptability**

No conclusions can be drawn on cost-effectiveness.

**Feasibility**

PFO closure is a widely standardised procedure worldwide.

**Subgroup considerations**

In our meta-analysis, only patients with aura experienced a statistically-significant improvement in migraine (Supplementary Table 8 – Supplementary Figure 3). This is in keeping with a previously published meta-analysis [77]

Moreover, in a previously published meta-analysis considering observational studies and one RCT only, patients with cerebrovascular disease were reported to have a statistically-significant improvement in migraine with PFO closure versus medical therapy [72].

The evidence of therapeutic efficacy in subgroups underscores the heterogeneity of this population and the need to better characterise key features.

**Implementation considerations**

No cost-effectiveness studies have been performed in this field.

**Monitoring and evaluation**

PFO closure may be proposed to patients only on a compassionate-use basis and after a thorough neurological evaluation and documented assessment of different medical therapies prescribed by migraine specialists. The cardiologist and neurologist must come to the conclusion that current therapy is insufficiently effective to allow for a good quality of life. Patients should be actively involved at all stages of management and their contribution to choices should be documented. Local registries providing prospective evaluations of outcomes are strongly encouraged.

**Research priorities**

- To identify high risk-phenotypes for a causal PFO, encompassing different clusters of clinical, anatomical and biological characteristics in prospective observational trials (systems and precision approaches)
- To design adequately dimensioned RCTs comparing PFO closure to medical therapy in specific high-risk subgroups (e.g., patients with migraine with aura and/or documented cerebrovascular disease).
- To perform new, cost-effectiveness analyses based on contemporary practices
- To obtain quantitative and qualitative data on patient preferences and values in the setting of migraine with PFO, and to involve patients in the design and choice of outcomes in the studies, particularly including in the outcomes the evaluation of post-critical quality of life after migraine attacks
- To design prospective registries to evaluate practices and outcomes in the real world
Supplementary Table 8. Detailed PICO question for therapy of migraine.

**PICO QUESTION**

Should percutaneous closure of PFO plus medical therapy vs medical therapy alone be used for reducing migraine?

| POPULATION: | Patients with migraine |
| INTERVENTION: | Percutaneous closure of PFO plus medical therapy |
| COMPARISON: | Medical therapy alone |

**ASSESSMENT**

**Problem**

Is the problem a priority?

<table>
<thead>
<tr>
<th>JUDGEMENT</th>
<th>RESEARCH EVIDENCE</th>
<th>ADDITIONAL CONSIDERATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>○ No</td>
<td>○ Probably no</td>
<td>○ Yes</td>
</tr>
<tr>
<td>○ Probably yes</td>
<td>● Yes</td>
<td>○ Varies</td>
</tr>
<tr>
<td>○ Don't know</td>
<td>○ Don't know</td>
<td>○ Varies</td>
</tr>
</tbody>
</table>

Migraine is a common neurological disorder which affects approximately 4.9% of men and 15-17% of women between 20 and 64 years of age [39] and is often disabling despite medical therapy [40]. It is estimated that 1-4% of the population meet criteria for chronic migraine [41,42]. In the general population, it is estimated that the prevalence of migraine with aura ranges from 1.2 to 37% in men and from 2.6 to 10.8% in women [43].

**Desirable effects**

How substantial are the desirable anticipated effects?

<table>
<thead>
<tr>
<th>JUDGEMENT</th>
<th>RESEARCH EVIDENCE</th>
<th>ADDITIONAL CONSIDERATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>○ Trivial</td>
<td>○ Small</td>
<td>○ Moderate</td>
</tr>
<tr>
<td>○ Large</td>
<td>● Varies</td>
<td>○ Don't know</td>
</tr>
</tbody>
</table>

Currently, data are available on 1,909 patients in 22 non-randomised comparisions, 3 randomised studies, one study-level meta-analysis including all RCTs, one study-level meta-analysis of observational trials and one RCT (MIST), and one study-level meta-analysis of eight observational trials, mostly retrospective studies (Supplementary Table 2, Supplementary Table 4, Supplementary Figure 2-Supplementary Figure 4).

All RCTs (MIST, PRIMA and PREMIUM trials) failed individually to show a greater efficacy for primary endpoints with PFO closure plus medical therapy versus medical therapy alone (Supplementary Appendix 2) [73–75].

Our updated study-level meta-analysis of observational and randomised case-control trials overall showed superiority of PFO closure over medical therapy for migraine incidence (odds ratio [OR] = 0.27 [95% CI: 0.11-0.66]), with severe heterogeneity across studies ($\chi^2=25.15, p=0.004; I^2=72\%$). However, the superior efficacy of PFO closure was driven by observational studies, whereas RCTs, enrolling only 414 patients, showed similar effects of interventional and medical therapies (OR = 0.86 [95% CI: 0.09-8.23]) (Supplementary Figure 2-Supplementary Figure 4).

Considering subgroups, relative to medical therapy, our meta-analyses showed significant improvement in migraine with PFO closure only in patients with aura (OR = 0.21 [95% CI: 0.12-0.37]) (Supplementary Figure 3).

Our additional analysis of before and after observational studies showed an overall improvement in migraine status with PFO closure (OR = 0.12 [95% CI: 0.07-0.21]) (Supplementary Figure 4).

Similarly, in the previously published meta-analysis of RCTs only [77], no statistically significant difference in complete resolution of migraine attacks (OR 3.67, 95% CI: 0.66–20.41) or in responder rate (OR 1.92, 95% CI: 0.76–4.85) was observed overall between PFO closure and control groups. However, a statistically significant higher reduction in the frequency and duration of monthly migraine attacks was observed in the PFO closure versus control group (standardised mean difference [SMD] 0.25; 95% CI: 0.66–0.43; p = 0.01 and SMD 0.30; 95% CI: 0.08–0.53; p = 0.01, respectively). Moreover, on subgroup analysis, a reduction in migraine attacks in the PFO closure versus control group was reported in patients with a majority of episodes accompanied by an aura (SMD 0.86; 95% CI: 0.07–1.65; p = 0.03). The other two previous meta-analyses, including a
smaller number of observational trials and one RCT, showed similar results, especially in patients with previous cerebral ischaemic injury or migraine with aura [72,76].

### Undesirable effects

**How substantial are the undesirable anticipated effects?**

<table>
<thead>
<tr>
<th>JUDGEMENT</th>
<th>RESEARCH EVIDENCE</th>
<th>ADDITIONAL CONSIDERATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>○ Large</td>
<td>Undesirable effects of percutaneous closure vs medical therapy have been scarcely and inconsistently reported in both RCTs and, especially, observational trials. In RCTs, the incidence of adverse effects related to the PFO closure procedure or to the device ranged from 0.5% to 1.1%. In our meta-analysis, incidence rates for undesirable procedure- or device-related adverse events in RCTs were similar with PFO closure vs medical therapy only (OR: 4.13, 95%CI: 0.34-49.53).</td>
<td></td>
</tr>
<tr>
<td>○ Moderate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>○ Small</td>
<td>Trivial</td>
<td></td>
</tr>
<tr>
<td>○ Varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>○ Don’t know</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Certainty of evidence

**What is the overall certainty of the evidence of effects?**

<table>
<thead>
<tr>
<th>JUDGEMENT</th>
<th>RESEARCH EVIDENCE</th>
<th>ADDITIONAL CONSIDERATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>○ Very low</td>
<td>The benefit for patients with unspecified migraine overall derives only from observational studies and, regarding specific measures, from meta-analyses of secondary endpoints in RCTs.</td>
<td></td>
</tr>
<tr>
<td>● Low</td>
<td>The benefit regarding patients with aura derives from only one RCT, influencing the results of the available meta-analyses, and from observational studies.</td>
<td></td>
</tr>
<tr>
<td>○ Moderate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>○ High</td>
<td></td>
<td></td>
</tr>
<tr>
<td>○ No included studies</td>
<td>The overall certainty of evidence is furthermore questioned by the judgement on individual studies, both for observational and RCTs (Supplementary Table 2, Supplementary Table 4).</td>
<td></td>
</tr>
</tbody>
</table>

All individual RCTs were underpowered (Supplementary Appendix 2 and Supplementary Table 2) and meta-analyses should be interpreted accordingly. Moreover, individual RCTs have low internal and external validity (Supplementary Appendix 2 and Supplementary Table 2, Supplementary Table 4) and the validity of one of the RCTs was severely criticised by some of the study’s own authors. Indeed, event rates were low and confidence intervals wide. Moreover, innumerable data from meta-analyses and randomised and observational studies (see text) show that substantial heterogeneity exists in the populations studied. Hence, more precise phenotyping with multidimensional data is warranted for future randomised trials. New research is needed to impact current estimates.

### Values

**Is there important uncertainty about or variability in how much people value the main outcomes?**

<table>
<thead>
<tr>
<th>JUDGEMENT</th>
<th>RESEARCH EVIDENCE</th>
<th>ADDITIONAL CONSIDERATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>○ Important uncertainty or variability</td>
<td>No specific studies assessing the priority of outcomes from patients suffering from PFO-associated migraine are available. In a study of 510 subjects with migraine, the impact of any therapy on the post-headache phase was a key determinant of patient preferences regarding treatment [192]. Unfortunately, none of the studies on PFO-associated migraine considered this aspect.</td>
<td></td>
</tr>
<tr>
<td>○ Possibly important uncertainty or variability</td>
<td>However, as migraine is a chronic, disabling disease, it is no surprise that three studies showed, in patients suffering from migraine at large, that the efficacy of headache treatment is more important to them than the treatment’s safety or route of administration [193–195]. Indeed, patients often even prefer device therapy (neurostimulation) to drug therapy when it is more effective [193]. Moreover, even though one of these studies also showed that patients are often satisfied with available drug prevention [194], in a recent study, migraineurs were more likely to fill the</td>
<td></td>
</tr>
<tr>
<td>● Probably no important uncertainty or variability</td>
<td></td>
<td></td>
</tr>
<tr>
<td>○ No important uncertainty or variability</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
variability prescription and adhere to the new therapy when their preferred dosing regimen was available [196].

Therefore, even though individual assessment of preferences is paramount, there is probably no important uncertainty or variability in how much patients value the main outcome of migraine improvement.

### Balance of effects
Does the balance between desirable and undesirable effects favor the intervention or the comparison?

<table>
<thead>
<tr>
<th>JUDGEMENT</th>
<th>RESEARCH EVIDENCE</th>
<th>ADDITIONAL CONSIDERATIONS</th>
</tr>
</thead>
</table>
| ○ Favours the comparison  
○ Probably favours the comparison  
○ Does not favour either the intervention or the comparison  
● Probably favours the intervention  
○ Favours the intervention  
○ Varies  
○ Don't know | The available data suggest that the intervention may potentially better benefit select patients with aura and/or cerebrovascular disease, with a similar incidence of adverse events to medical therapy. Adverse events associated with a percutaneous procedure and/or the device were mostly mild and transient, whereas adverse events related to life-long medical therapy can be persistent. However, given the high uncertainty of results, more adequately designed studies are necessary to confirm these findings. | |

### Acceptability
Is the intervention acceptable to key stakeholders?

<table>
<thead>
<tr>
<th>JUDGEMENT</th>
<th>RESEARCH EVIDENCE</th>
<th>ADDITIONAL CONSIDERATIONS</th>
</tr>
</thead>
</table>
| ○ No  
○ Probably no  
○ Probably yes  
○ Yes  
○ Varies  
● Don't know | No cost-effectiveness evaluation comparing different medical therapies versus percutaneous closure of PFO has been performed in migraineurs. | |

### Feasibility
Is the intervention feasible to implement?

<table>
<thead>
<tr>
<th>JUDGEMENT</th>
<th>RESEARCH EVIDENCE</th>
<th>ADDITIONAL CONSIDERATIONS</th>
</tr>
</thead>
</table>
| ○ No  
○ Probably no  
○ Probably yes  
● Yes  
○ Varies  
○ Don't know | PFO closure is a well-established technique performed at many interventional centres across the globe. | |
Supplementary Table 9. Characteristics of the studies on PFO closure for migraine.

<table>
<thead>
<tr>
<th>First author</th>
<th>Design</th>
<th>FUP (years)</th>
<th>Endpoint</th>
<th>Migraine</th>
<th>Drugs</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anzola [197]</td>
<td>Prospective</td>
<td>1</td>
<td>Migraine score</td>
<td>Improvement of migraine score</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Araszkiewicz [198]</td>
<td>Prospective</td>
<td>1.5</td>
<td>No. of patients with migraine</td>
<td>Reduction from 30% to 15.7% after the procedure</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Azarbal [199]</td>
<td>Prospective</td>
<td>0.4</td>
<td>No. of patients with migraine</td>
<td>Reduction from 42% to 31% after the procedure</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Biasco [200]</td>
<td>Retrospective</td>
<td>0.5</td>
<td>No. of patients with migraine</td>
<td>Improvement of migraine score</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Dubiel [201]</td>
<td>Retrospective</td>
<td>2</td>
<td>No. of patients with migraine</td>
<td>Improvement of migraine score</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Giardini [202]</td>
<td>Retrospective</td>
<td>1.7</td>
<td>No. of patients with migraine</td>
<td>Reduction from 100% to 17% after the procedure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jesurum [203]</td>
<td>Retrospective</td>
<td>2</td>
<td>No. of patients with migraine</td>
<td>Reduction from 71% to 44% after the procedure</td>
<td>NA</td>
<td>No improvement at multivariate analysis</td>
</tr>
<tr>
<td>Khessali [46]</td>
<td>Prospective</td>
<td>1</td>
<td>No. of patients with migraine</td>
<td>Reduction from 100% to:</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- 52% for those with visual aura</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- 75% for aura not related to migraine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- 80% in aura without migraine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kimmelstiel [204]</td>
<td>Prospective</td>
<td>1</td>
<td>Patients with migraine and migraine score</td>
<td>Reduction from 100% to 17% and reduction in score</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Author</td>
<td>Study Design</td>
<td>n</td>
<td>Population</td>
<td>Outcome Measures</td>
<td>Results</td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------</td>
<td>---</td>
<td>------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Luermans [205]</td>
<td>Retrospective</td>
<td>2</td>
<td>Patients with migraine and migraine score</td>
<td>Reduction of severity of migraine</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Milev [206]</td>
<td>Retrospective</td>
<td>2</td>
<td>Patients with migraine</td>
<td>Reduction of severity of migraine</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Morandi [207]</td>
<td>Prospective</td>
<td>0.5</td>
<td>Patients with migraine</td>
<td>Reduction from 100% to 29%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Post [208]</td>
<td>Retrospective</td>
<td>0.3</td>
<td>Patients with migraine</td>
<td>Reduction from 39.4% to 15.1%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Reisman [209]</td>
<td>Prospective</td>
<td>0.9</td>
<td>Patients with migraine</td>
<td>Reduction from 100% to 44%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Rigatelli [210]</td>
<td>Prospective</td>
<td>1</td>
<td>MIDAS score</td>
<td>100% reported an improvement of MIDAS score. Aura disappeared in all of the patients</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Schwerzmann [211]</td>
<td>Retrospective</td>
<td>1</td>
<td>Number of migraine attacks</td>
<td>Relative reduction of 54% in those with aura and 62% in those without</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Trabattoni [212]</td>
<td>Prospective</td>
<td>1</td>
<td>No. of patients with migraine</td>
<td>Reduction from 100% to 54%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Vigna [71]</td>
<td>Prospective</td>
<td>1</td>
<td>No. of patients with migraine</td>
<td>Reduction from 100% to 66%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Wahl [213]</td>
<td>Prospective</td>
<td>1</td>
<td>No. of patients with migraine</td>
<td>Reduction from 100% to 34%</td>
<td>Reduction of patients assuming drugs</td>
<td>NA</td>
</tr>
<tr>
<td>Dowson [73]</td>
<td>RCT</td>
<td>0.3-0.6</td>
<td>Migraine headache cessation</td>
<td>No significant reduction of patients with migraine. Reduction in PFO closure of days of migraine</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Tobis [75]</td>
<td>RCT</td>
<td>1</td>
<td>50% reduction in attacks</td>
<td>No difference in primary endpoint. PFO significantly reduced headache days and complete remission</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>First author</td>
<td>Design</td>
<td>FUP (years)</td>
<td>Endpoint</td>
<td>Migraine</td>
<td>Drugs</td>
<td>Multivariate analysis</td>
</tr>
<tr>
<td>--------------</td>
<td>--------</td>
<td>-------------</td>
<td>----------</td>
<td>----------</td>
<td>-------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Elbadawi [77]</td>
<td>Meta-analysis</td>
<td>0.5</td>
<td>Reduction in migraine attacks/months (NNT of 13 assuming a reduction of 1.9 as expected outcome)</td>
<td>PFO closure reduced migraine attacks/months (NNT of 13 assuming a reduction of 1.9 as expected outcome) without leading to migraine resolution</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Kheiri [214]</td>
<td>Meta-analysis</td>
<td>0.5</td>
<td>Reduction in migraine attacks/months</td>
<td>PFO closure reduced migraine attacks and its length</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Shi [76]</td>
<td>Meta-analysis</td>
<td>1</td>
<td>Elimination or significant improvement of migraine symptoms after PFO closure</td>
<td>Reduction in migraine attacks more evident in migraine with aura</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Butera [72]</td>
<td>Meta-analysis</td>
<td>1</td>
<td>Cured or significantly improved migraine</td>
<td>46% with complete resolution, 83% with at least partial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Supplementary Table 10. Diseases in which PFO can contribute to arterial hypoxaemia and its clinical consequences.

<table>
<thead>
<tr>
<th>DISEASE</th>
<th>SHUNT CAUSES</th>
<th>CLINICAL CONSEQUENCES</th>
<th>PFO PATHOGENIC ROLE</th>
</tr>
</thead>
</table>
| **Platypnoea-orthodeoxia syndrome (POS)**          | - Pulmonary hypertension (ventilation/perfusion mismatch) [182]  
- Preferential blood flow towards the PFO from the inferior vena cava (through prominent Eustachian valve or deformation of atrial structures, due to cardiac valve disease, or diaphragmatic, pulmonary, vertebral column, or aortic disease [184-191] | - Upright position dyspnoea relieved by lying supine                                                                                                         | VERY FREQUENT [80]                          |
| **Obstructive sleep apnoea syndrome (OSAS)**       | - Intermittent and then persistent pulmonary hypertension due to apnoea with hypoxaemia and hypercapnia causing vasoconstriction  
- Fluctuations in intrathoracic pressure during apnoea                                                                                                 | - Exacerbation of hypoxaemia during apnoeic episodes [169-171]  
- More OSAS-related symptoms and at an earlier stage than in those without a PFO [169]                                                               | POSSIBLE                                     |
| **Chronic obstructive pulmonary disease (COPD)**   | - Pulmonary hypertension due to chronic ventilation-perfusion mismatch [172]                                                                                                                                   | - No clinical effect [174]  
- Transient oxygen desaturation [172]  
- Arterial oxygen saturation lower than expected given the clinical picture [175]  
- Lower exercise tolerance [175]                                                                                                                          | DEBATED                                     |
| Exercise desaturation                              | - Pulmonary hypertension                                                                                                                                                                                     | - Reduced exercise tolerance                                                                             | UNDER INVESTIGATION                        |
| **High-altitude pulmonary oedema (HAPO)**         | - Pulmonary hypertension due to hypoxia [177]                                                                                                                                                              | - Aggravation of hypoxaemia and pulmonary oedema                                                          | UNDER INVESTIGATION                        |
### Supplementary Table 11 - Summary of statements on arterial deoxygenation and PFO

<table>
<thead>
<tr>
<th>Position Statements</th>
<th>Strength of the statement</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFO has the potential to generate clinically significant right-to-left shunts, often only aggravating pre-existing arterial oxygen desaturation</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>Assessing the role of a PFO in hypoxaemia should be done only if an interdisciplinary, comprehensive evaluation of all possible factors causing hypoxaemia fails to fully explain the clinical picture</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>A catheterisation lab assessment of left atrial SaO$_2$ (including each pulmonary vein), pulmonary pressures and a balloon occlusion test should be performed when the role of PFO is not straightforward.</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>Pulmonary causes of hypoxaemia (particularly pulmonary embolism, intrapulmonary shunts and severe pulmonary hypertension) should be ruled out before considering PFO closure.</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>In patients with PFO-related platynoea-orthodeoxia syndrome and without severe pulmonary hypertension, percutaneous closure of the PFO is a first-line treatment</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>Percutaneous closure of a PFO can be proposed to patients with any desaturation syndrome in which, despite best conventional treatment, the PFO has been demonstrated to unequivocally and critically contribute to the arterial desaturation and symptoms</td>
<td>Conditional</td>
<td>C</td>
</tr>
</tbody>
</table>

**RESEARCH AGENDA:**
- To assess the incidence of significant PFO-related arterial hypoxaemia in the different syndromes
- To identify high-risk phenotypes for clinically significant PFO-related arterial desaturation encompassing different clusters of clinical, anatomical and biological characteristics in prospective observational trials (systems and precision approaches)
- To design adequately dimensioned observational studies and RCTs comparing PFO closure vs medical therapy only, in different syndromes
- To obtain quantitative and qualitative data on patient preferences and values
### Supplementary Table 12. Position statements on pregnancy and the pre-operative management of patients.

<table>
<thead>
<tr>
<th>Position Statements</th>
<th>Strength of the statement</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PREGNANCY, DELIVERY AND THE PUERPERIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outside of research, in unselected healthy, asymptomatic women planning a pregnancy or during a normal pregnancy, PFO should not be systematically screened for.</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>Outside of research, in women with a known PFO but otherwise without coagulation diseases, no primary prevention for thrombotic systemic embolism should be foreseen.</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>Secondary prevention of PFO-related thrombotic systemic emboli in women of child-bearing age or during pregnancy should be done according the statements published in the first part of this document [1,2] taking into due consideration the risk of irradiation during pregnancy in cases of percutaneous PFO closure.</td>
<td>Conditional</td>
<td>C</td>
</tr>
<tr>
<td><strong>RESEARCH AGENDA:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- To assess a possible link between PFO and thrombotic systemic embolism in pregnancy, delivery and puerperium</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>- Epidemiological, systems and precision medicine research to identify possible phenotypes at high risk of thrombotic systemic embolism during pregnancy, delivery and the puerperium</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PRE-OPERATIVE EVALUATION FOR NON-CARDiac SURGERY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outside of research, in unselected healthy, asymptomatic patients, PFO should not be systematically screened for during preoperative evaluations for non-cardiac surgery</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>In asymptomatic patients with a known PFO, there is insufficient data to render decisions regarding any form of primary prevention, pharmaceutical or interventional, for thrombotic systemic embolism</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>Patients at high risk of perioperative thrombosis should be managed according to existing guidelines on the topic, irrespective of the presence of a PFO</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td><strong>RESEARCH AGENDA:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- To prospectively assess the incidence of PFO-related perioperative thrombotic systemic embolism</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>- To identify high-risk phenotypes for PFO-related thrombotic systemic embolism encompassing different clusters of clinical, anatomical and biological characteristics in prospective observational trials (systems and precision approaches)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- To design adequately dimensioned observational studies and RCTs comparing PFO closure vs medical therapy only, to prevent perioperative thrombotic systemic embolism</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Supplementary Table 13. Position statements regarding neurosurgery in the sitting position.**

<table>
<thead>
<tr>
<th>Position Statements</th>
<th>Strength of the statement</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients scheduled for neurosurgery in the sitting position should routinely undergo screening for a PFO prior to surgery</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>In patients with a PFO, neurosurgery in the sitting position is contraindicated; but neurosurgery in a horizontal surgical position also needs to be monitored closely.</td>
<td>Strong</td>
<td>C</td>
</tr>
<tr>
<td>In select patients with a PFO in whom the neurosurgical operation can be delayed 1-12 months (preferably 6-12) and: a) the sitting position is mandatory or b) a previous attempt at surgery in a prone or lateral position led to a venous air embolism, PFO closure is reasonable, followed by neurosurgery at a later date after assessing completeness of closure</td>
<td>Conditional</td>
<td>C</td>
</tr>
</tbody>
</table>

**RESEARCH AGENDA:**
- To assess the efficacy and safety of percutaneous closure of a PFO to prevent cerebral air emboli during neurosurgery in the sitting position, both observational and randomised controlled studies are needed.

<table>
<thead>
<tr>
<th>Strength of the statement</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong</td>
<td>C</td>
</tr>
</tbody>
</table>
Supplementary Table 14. GRADE evaluation of certitude of effects – DCS.

A. Professional divers

<table>
<thead>
<tr>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>Certainty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observational</td>
<td>Serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Very serious</td>
<td>Dose response gradient</td>
<td>Very low</td>
</tr>
<tr>
<td>studies</td>
<td>a</td>
<td>b</td>
<td>c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Explanations
a. High risk of adjudication bias
b. No multivariate analysis and no sample size calculation
c. There is a (imperfect) dose-response relation between deep diving and generation of nitrogen emboli after the dive; based on Doppler studies (Nishi, Effedal) there is also a (imperfect) relation between numbers/grade of nitrogen bubbles and risk of DCS.

B. Recreational divers

<table>
<thead>
<tr>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>Certainty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observational</td>
<td>Serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Very serious</td>
<td>None</td>
<td>Very low</td>
</tr>
<tr>
<td>studies</td>
<td>a</td>
<td>b</td>
<td>c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Explanations
a. High risk of blinding and of adjudication of events
b. Few studies with multivariate analysis and no sample size calculation
### Supplementary Table 15. Studies on DCS in recreational divers.

<table>
<thead>
<tr>
<th>First author</th>
<th>Sample size</th>
<th>Incidence of PFO</th>
<th>Design</th>
<th>Causal association</th>
<th>Follow up data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Billinger [215]</td>
<td>106 scuba divers</td>
<td>48 (29%)</td>
<td>Retrospective</td>
<td>NN</td>
<td>NN</td>
</tr>
<tr>
<td>Gempp [21]</td>
<td>47 divers</td>
<td>24 recurrent cases of DCS</td>
<td>Prospective</td>
<td>Large right to left shunts are associated with repeated episodes</td>
<td>NN</td>
</tr>
<tr>
<td>Honek [29]</td>
<td>532 divers</td>
<td>46 (8.4%)</td>
<td>Prospective</td>
<td>A significant reduction of DCS risk was observed after recommendation of conservative profile for the whole group as well as for the subgroups with or without a r/l shunt.</td>
<td>NN</td>
</tr>
<tr>
<td>Liou [145]</td>
<td>75 divers</td>
<td>39 (52)</td>
<td>Retrospective</td>
<td>Major DCS was observed significantly more commonly in divers with PFO than in those without</td>
<td>NN</td>
</tr>
<tr>
<td>Moon [13]</td>
<td>30 divers (26 sport + 4 professional) and 176 controls</td>
<td>NN</td>
<td>Prospective</td>
<td>Higher incidence of DCS in controls</td>
<td></td>
</tr>
<tr>
<td>Pearman [33]</td>
<td>105 divers with PFO closure</td>
<td>105/105</td>
<td>Retrospective</td>
<td>2/105 had AF. 2/105 residual shunt</td>
<td></td>
</tr>
<tr>
<td>Torti [144]</td>
<td>230</td>
<td>63 (27)</td>
<td>Retrospective</td>
<td>PFO increases of 5 risk of DCS</td>
<td></td>
</tr>
<tr>
<td>Wilmshurst [14] *</td>
<td>60 divers (57 recreational + 3 professionals)</td>
<td></td>
<td>Retrospective</td>
<td>Higher incidence of RtoL shunt in divers with DCS</td>
<td></td>
</tr>
</tbody>
</table>

*included in quantitative analysis
Supplementary Table 16. Studies on DCS in professional divers.

<table>
<thead>
<tr>
<th>First author</th>
<th>Sample size</th>
<th>Incidence of PFO</th>
<th>Design</th>
<th>Causal association</th>
<th>Follow-up data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cantais [11] *</td>
<td>202 (101 DCS, 101 control)</td>
<td>N</td>
<td>Prospective</td>
<td>Major right to left shunt is associated with DCS</td>
<td>NN</td>
</tr>
<tr>
<td>Cartoni [22]</td>
<td>66 (41 with DCS, 25 without)</td>
<td>35/66 (53%)</td>
<td>Retrospective</td>
<td>PFO with right-to-left shunting at rest is associated with decompression illness</td>
<td>NN</td>
</tr>
<tr>
<td>Germonpre [12]*</td>
<td>74 (37 divers with DCS vs 37 divers without)</td>
<td>22/37 (60%) divers with DCS and 13/37 (36%) divers without</td>
<td>Prospective</td>
<td>Higher incidence of PFOs in divers with DCS compared with those without</td>
<td>NN</td>
</tr>
<tr>
<td>Honek [31]</td>
<td>47 divers</td>
<td>47/47</td>
<td>Prospective</td>
<td>PFO closure reduced arterial bubbles</td>
<td>NN</td>
</tr>
<tr>
<td>Klingmann [28]</td>
<td>27 divers</td>
<td>4 with PFO closure</td>
<td>Retrospective</td>
<td>A highly significant reduction of DCS risk was observed after recommendation of conservative profile for the whole group as well as for the subgroups with or without a r/l shunt.</td>
<td>NN</td>
</tr>
<tr>
<td>Wilmshurst [146]</td>
<td>200 divers</td>
<td>200/200</td>
<td>Retrospective</td>
<td>Larger atrial defect in divers experiencing DCS</td>
<td>NN</td>
</tr>
<tr>
<td>Pearman [33]</td>
<td>105 divers with PFO closure</td>
<td>105/105</td>
<td>Retrospective</td>
<td>2/105 had AF. 2/105 residual shunt</td>
<td>NN</td>
</tr>
<tr>
<td>Walsh [32]</td>
<td>7 divers with DS</td>
<td>1/7</td>
<td>Retrospective</td>
<td>NN</td>
<td>NN</td>
</tr>
</tbody>
</table>

* included in quantitative analysis
Supplementary Table 17. GRADE evaluation of certitude of effects – desaturation syndromes.

<table>
<thead>
<tr>
<th>Nuovo esito</th>
<th>No of studies</th>
<th>Study design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>Certainty</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5</td>
<td>Observational studies</td>
<td>Serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Serious</td>
<td>None</td>
<td>VERY LOW</td>
</tr>
</tbody>
</table>

CI: confidence interval

**Explanations**

- a. High risk of adjudication of outcomes
- b. No sample size calculation
References

1. Pristipino C, Sievert H, D’Ascenzo F, Mas JL, Meier B, Scacciatella P, Hildick-Smith D, Gaita F, Toni D, Kyrle P, Thomson J, Derumeaux G, Onorato E, Sibbing D, Germonpré P, Berti S, Chessa M, Bedogni F, Dudek D, Hornung M, Zamorano J; European Association of Percutaneous Cardiovascular Interventions (EAPCI); European Stroke Organisation (ESO); European Heart Rhythm Association (EHRA); European Association for Cardiovascular Imaging (EACVI); Association for European Paediatric and Congenital Cardiology (AEPC); ESC Working group on GUCH; ESC Working group on Thrombosis; European Haematological Society (EHA). European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. EuroIntervention. 2019;14:1389-402.


14. Wilmshurst PT, Pearson MJ, Walsh KP, Morrison WL, Bryson P. Relationship between right-to-


123. Carroll JD. PFO and Various Types of Surgery. In: Amin Z, Tobis JM, Sievert H, Carroll JD,


